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Review Article

Lysosomal storage diseases
Carlos R. Ferreiraa,b,c,∗ and William A. Gahlc
a

Division of Genetics and Metabolism, Children’s National Health System, Washington, DC, USA
George Washington University School of Medicine & Health Sciences, Washington, DC, USA
c
Human Biochemical Genetics Section, Medical Genetics Branch, National Human Genome
Research Institute, National Institutes of Health, Bethesda, MD, USA
b

Abstract. Lysosomes are cytoplasmic organelles that contain a variety of different hydrolases. A genetic deficiency in the
enzymatic activity of one of these hydrolases will lead to the accumulation of the material meant for lysosomal degradation.
Examples include glycogen in the case of Pompe disease, glycosaminoglycans in the case of the mucopolysaccharidoses,
glycoproteins in the cases of the oligosaccharidoses, and sphingolipids in the cases of Niemann-Pick disease types A and B,
Gaucher disease, Tay-Sachs disease, Krabbe disease, and metachromatic leukodystrophy. Sometimes, the lysosomal storage
can be caused not by the enzymatic deficiency of one of the hydrolases, but by the deficiency of an activator protein, as
occurs in the AB variant of GM2 gangliosidosis. Still other times, the accumulated lysosomal material results from failed
egress of a small molecule as a consequence of a deficient transporter, as in cystinosis or Salla disease. In the last couple of
decades, enzyme replacement therapy has become available for a number of lysosomal storage diseases. Examples include
imiglucerase, taliglucerase and velaglucerase for Gaucher disease, laronidase for Hurler disease, idursulfase for Hunter
disease, elosulfase for Morquio disease, galsulfase for Maroteaux-Lamy disease, alglucosidase alfa for Pompe disease, and
agalsidase alfa and beta for Fabry disease. In addition, substrate reduction therapy has been approved for certain disorders,
such as eliglustat for Gaucher disease. The advent of treatment options for some of these disorders has led to newborn
screening pilot studies, and ultimately to the addition of Pompe disease and Hurler disease to the Recommended Uniform
Screening Panel (RUSP) in 2015 and 2016, respectively.
Keywords: Lysosomal storage diseases, Niemann-Pick disease, Gaucher disease, Krabbe disease, Farber disease, Fabry
disease, Schindler disease, GM1 gangliosidosis, Tay-Sachs disease, Sandhoff disease, metachromatic leukodystrophy,
cystinosis, free sialic acid storage disease, mucolipidosis IV, newborn screening

1. Lysosomal structure and function
Lysosomes are membrane-enclosed cytoplasmic organelles with a diameter of 0.05 to 0.5 m [1].
They were discovered serendipitously by Christian de Duve in 1955, in his laboratory in Leuven,
Belgium. He was studying the effects of insulin in the liver, and he surmised that knowing the subcellular
localization of glucose-6-phosphatase might provide a clue to understanding the hepatic action of
insulin. As a control, he tracked the activity and subcellular locatization of acid phosphatase. He
homogenized rat livers using two different techniques: Albert Claude’s method, a mild procedure by
which cellular organelles are kept intact, and a coarser method using a kitchen blender. The activity of
acid phosphatase was much higher when measured in homogenates obtained with the kitchen blender,
and also after thawing samples that were kept in the refrigerator. This and subsequent lines of evidence
led him to propose that acid phosphatase –and other enzymes- were sequestered within membranebound organelles. Refinements of fractionation methods by centrifugation led to the discovery of
∗
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“lytic bodies”, or lysosomes. He never returned to insulin research, but decided to focus on cell
structure instead. Ten years later, in 1965, he also discovered peroxisomes. He received the Nobel
Prize in Physiology or Medicine in 1974, for his discovery “concerning the structural and functional
organization of the cell” [2, 3].
Lysosomes contain a variety of active hydrolytic enzymes (hydrolases) such as glycosidases, sulfatases, phosphatases, lipases, phospholipases, proteases, and nucleases (lysosomal enzymes) in an acid
milieu (pH approximately 5). Most lysosomal enzymes enter a lysosome by means of a recognition
signal (usually mannose-6-phosphate) and its corresponding receptors [4].
Extracellular molecules to be degraded are taken into the cell by a variety of means, one of which
is receptor-mediated endocytosis. First, the molecules are bound to specific cell surface receptors.
The loaded receptors are concentrated in an invagination of the plasma membrane (coated pit). This
separates from the plasma membrane and forms a membrane-enclosed cytoplasmic compartment
(coated vesicle). Hormones, growth factors, energy-delivering proteins, and numerous viruses and
toxins also enter cells by receptor-mediated endocytosis. The cytoplasmic lining of the vesicle consists
of a network of a trimeric protein called clathrin. The clathrin coat is quickly lost within the cell and
an endosome forms; the endosome fuses with membrane vesicles from the Golgi apparatus to form
larger endosomal compartments [4]. Once within lysosomes, macromolecules (lipids, carbohydrates,
proteins) are degraded by hydrolytic enzymes to form their respective terminal components (fatty
acids, monosaccharides, amino acids), which subsequently exit the lysosome.
The deficiency of a single hydrolase will create an inability to degrade the rest of the macromolecule.
The end result is a lysosomal storage disease, and lysosomal enzymes undergo a complex multi-step
process from gene transcription in the nucleus to functional protein within the lysosome. Messenger
RNA, coding for a lysosomal enzyme, is directed to membrane-bound ribosomes of the rough endoplasmic reticulum, at which site the enzyme polypeptide is constructed. Next, an NH2 -terminal signal
peptide directs the polypeptide into the lumen of the endoplasmic reticulum. Typically, the polypeptide
is then targeted to the lysosome by the addition of mannose-6-phosphate to the N-linked oligosaccharide
side chains of the polypeptide. Many lysosomal hydrolases undergo further proteolytic cleavage before
becoming fully activated. Defects in the targeting of lysosomal enzymes to the lysosome have been
documented in mucolipidosis II and III. However, alternative ways of targeting the lysosomes, independent of mannose-6-phosphate, also exist. As an example, glucocerebrosidase enters the lysosome
by binding to LIMP-2, while acid sphingomyelinase, prosaposin and the GM2 Activator Protein use
sortilin as their receptor [5]. Receptor-mediated endocytosis and lysosome formation is shown in Fig. 1.
For some lysosomal hydrolases to be fully active, activator proteins must be present; mutations
affecting these activator proteins mimic deficiency of the hydrolase. The group of activator proteins
consists of 4 small nonenzymatic glycoproteins called Sphingolipid Activator Proteins, or SAPs, plus
the GM2 Activator Protein [6]. A SAP precursor, or prosaposin, gives rise to the 4 SAP proteins. It
contains 524 amino acids and 5 N-glycosylation sites with 4 homologous domains of approximately
80 amino acids each. Most of the precursor is exported to the cell surface and then imported into the
lysosomal compartment, where it is processed to the mature glycoproteins sap-A, sap-B, sap-C, and
sap-D. The SAP precursor gene resides on chromosome 10 while the ganglioside GM2 activator gene
is on chromosome 5 [7]. The primary lysosomal enzymes affected by activator protein deficiencies are
listed in Table 1, along with the associated diseases.
In addition to lysosomal enzyme and activator defects, there exist five known disorders of lysosomal membrane transport, each of which reflects the inability to carry a small molecule out of the
lysosome and into the cytoplasm. In these diseases (i.e., cystinosis, Salla disease, cobalamin F and
cobalamin J disease, and mucolipidosis type IV), the intralysosomal material consists of an amino
acid, monosaccharide, a cofactor, and cations, respectively, in contrast to the enzyme deficiencies, in
which a macromolecule is stored.
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Fig. 1. Receptor-mediated and lysosome formation. (Courtesy of Dr. Eberhard Passarge and Thieme Medical Publishers.).

Table 1
Sphingolipid activator proteins
Activator

Activated Enzyme

Disease

SAP A
SAP B
SAP C
SAP D
GM2 Activator Protein

␤-Galactosylceramidase
Arylsulfatase A; ␣-Galactosidase
␤-Glucosylceramidase
Sphingomyelinase
␤-Hexosaminidase A

Krabbe
Metachromatic Leukodystrophy
Gaucher
Niemann-Pick
GM2 AB variant∗

∗

Resembles Tay-Sachs disease.

Patients with lysosomal storage disorders are generally normal at birth, with symptoms developing
in the first year of life. However, pathological findings can appear in the fetus. In a 9-week fetus with
Tay-Sachs disease, lamellar and granular inclusions were present in the developing brain neurons. In
fetuses from 12 to 22 weeks’ gestation, the lysosomal inclusions are more typical of membranous
cytoplasmic bodies and are found in anterior horn cells of the spinal cord, ganglion cells of the retina,
enteric plexus, and spinal ganglia [8, 9].
Many different cell types and tissues are affected by lysosomal storage disorders, with involvement at
different stages in the disease process. Evaluation of these tissues through histology, enzymatic analysis,
or imaging can assist in the diagnosis. Tissues that are useful in the diagnosis of storage diseases are
listed in Table 2. Those disorders in which there is recognized peripheral blood, bone marrow, and
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Table 2
Tissues useful in the diagnosis of storage diseases

Organ

Manifestation

Disease to be
Considered

Procedure∗

Diagnostic Test∗

Liver

Hepatomegaly;
Elevated liver
function tests
(occasionally)

Cholesteryl ester storage
disease

Liver biopsy

Fibroblast or DBS lipase

Mucopolysaccharidoses
(MPS)
Glycoproteinoses
Mucolipidoses II, III

Urine MPS

Enzyme analysis

Urine oligosaccharides
Blood draw

Spleen

Bone and
Joint

Eye

Splenomegaly

Dysostosis
multiplex
Swollen joints, soft
tissue nodules
Macular cherry-red
spot

Glycogen storage
disease type II

Liver biopsy

Gaucher disease

Liver, bone marrow biopsy

Niemann-Pick disease

Liver biopsy

Wolman disease

Liver biopsy

Mucopolysaccharidoses
Gaucher disease

Urine MPS
Liver, bone marrow biopsy

Niemann-Pick disease

Liver biopsy, blood draw

Mucopolysaccharidoses

Urine MPS

Enzyme analysis
Serum (increased) or
fibroblast (decreased)
enzyme analysis
Lymphocyte, DBS or
fibroblast ␣-glucosidase;
electron microscopy
Leukocyte, DBS or
fibroblast
␤-glucocerebrosidase;
electron microscopy
Leukocyte, DBS or
fibroblast
sphingomyelinase
Electron microscopy;
fibroblast or DBS acid
lipase
Enzyme analysis
Leukocyte, DBS or
fibroblast
␤-glucocerebrosidase;
electron microscopy
Leukocyte, DBS or
fibroblast
sphingomyelinase
Enzyme analysis

Glycoproteinoses
Farber disease

Urine oligosaccharides
Tissue biopsy

Enzyme analysis
Fibroblast acid ceramidase

Tay-Sachs disease

Blood draw

Sandhoff disease

Blood draw

Niemann-Pick disease

Liver biopsy

Serum, leukocyte or
fibroblast
hexosaminidase A
Serum, leukocyte or
fibroblast total
hexosaminidase
Leukocyte, DBS or
fibroblast
sphingomyelinase
(Continued)
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Table 2
(Continued)
Organ

Manifestation

Corneal clouding

Adrenal
gland
MuscleCardiac
Skeletal

Brain

∗

Corneal crystals
Bilateral adrenal
calcifications
Cardiomegaly,
heart failure,
myopathy

Mental and motor
dysfunction

Disease to be
Considered

Procedure∗

Diagnostic Test∗

GM1 gangliosidosis

Urine oligosaccharides

Sialidoses
Mucopolysaccharidoses
Mucolipidoses II, III

Urine oligosaccharides
Urine MPS
Blood draw

Cystinosis
Wolman disease

Blood draw
Liver biopsy

Glycogen storage
disease type II

Liver biopsy

Glycogen storage
disease types III, IV
Krabbe disease

Liver biopsy

Leukocyte, DBS or
fibroblast
␤-galactosidase
Fibroblast sialidase
Enzyme assay
Serum (increased) or
fibroblast (decreased)
enzyme analysis
Leukocyte cystine
Fibroblast or DBS acid
lipase
Lymphocyte, DBS or
fibroblast ␣-glucosidase;
electron microscopy
Enzyme assay; electron
microscopy
Leukocyte, DBS or
fibroblast
␤-galactosidase
Leukocyte, DBS or
fibroblast arylsulfatase
A
Electron microscopy for
ceroid; enzyme assay for
the most common forms
Leukocyte, DBS or
fibroblast
sphingomyelinase
Leukocyte, DBS or
fibroblast
␤-glucocerebrosidase;
electron microscopy
Enzyme assay
Enzyme assay
Serum, leukocyte or
fibroblast
hexosaminidase A
Serum, leukocyte or
fibroblast total
hexosaminidase
Leukocyte, DBS or
fibroblast
␤-galactosidase

Blood draw; skin biopsy

Metachromatic
leukodystrophy

Blood draw; skin biopsy

Neuronal ceroid
lipofuscinosis

Blood draw; skin biopsy

Niemann-Pick disease

Liver biopsy

Gaucher disease

Liver, bone marrow biopsy

Mucopolysaccharidoses
Glycoproteinoses
Tay-Sachs disease

Urine MPS
Urine oligosaccharides
Blood draw; skin biopsy

Sandhoff disease

Blood draw; skin biopsy

GM1 gangliosidosis

Urine oligosaccharides

Most disorders are now diagnosed on molecular grounds, and invasive biopsies are not required. DBS: dried blood spot.
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Table 3
Lysosomal storage diseases with peripheral blood, bone marrow, and conjunctival/skin pathology
Conjunctival/Skin Biopsy

Disease

Peripheral
Bone Marrow Inclusion Type
Leukocytes
Foamy
Histiocytes

Site

Niemann-Pick disease
Gaucher disease

VL
–

+
+

Ep, En, M, N
Ep

Krabbe disease
Metachromatic leukodystrophy
Farber disease

–
–
–

–
+

Glycogen storage disease type II
GM1 Gangliosidosis
Tay-Sachs disease
Sandhoff disease
Fabry disease
Wolman disease
Mucopolysaccharidoses I, II, III
Mucolipidosis II
Mucolipidosis III
Mucolipidosis IV
Fucosidosis
Mannosidosis
Aspartylglucosaminuria
Galactosialidosis
Cystinosis
Sialic acid storage disease

VL
VL
–
–
–
VL
NG, VL
VL
VL
VL
VL
VL
VL
VL
–
VL

–
+
–
–
–
+
+
–
–
–
+
+
–
+
+
+

Pleomorphic, dense-lucent, lamellar
Non-lamellar clefts and immature
lamellar membranes (only in type 2)
Crystal-like
Herringbone
Tubular, “banana bodies”, granular,
membranous
Granular
Fibrillogranular, membranous
Membranous, granular
Membranous, granular
Lamellar
Vacuolar, membranous
Fibrillogranular, membranous
Fibrillogranular, lamellar
Fibrillogranular, lamellar
Fibrillogranular, lamellar
Fine granular, sparse
Fibrillogranular
Fibrillogranular
Fibrillogranular
Crystals
Granular, sparse

N
N
M, En, N
Ep, M, En, N
Ep, En, M, N
N, En, M
N, En, M
En, M
En, M
Ep, M, N, En
M, En, N
M, En, N
Ep, En, M, N
Ep, En, M, N
M, En, N
En, M, N
Ep, M
M
En, M

Ep, epithelial; En, endothelial; M, mesenchymal (histiocytes); N, neural; NG, neutrophil granules; VL, vacuolated lymphocytes.

conjunctival or skin pathology are shown in Table 3 and metabolic disorders with placental and/or fetal
pathology are shown in Table 4.
2. Lysosomal storage diseases due to enzyme defects
Lysosomal enzyme deficiencies can be categorized based upon the macromolecule that fails to be
degraded and is consequently stored. Carbohydrates, for example, are stored in glycogen storage disease
type II, or Pompe disease. Neutral lipids (triglycerides and cholesteryl esters) are stored in Wolman
disease and cholesteryl ester storage disease. Glycolipids accumulate in mucolipidoses. Glycoproteinoses involve deficiencies of enzymes that degrade the glycans that decorate glycoproteins [10];
these are largely N-linked sugar trees. The resulting diseases, named for the sugar that is not hydrolyzed,
include fucosidosis, ␣- and ␤-mannosidosis, sialidosis, and aspartylglucosaminuria. The former disorders are screened by urine oligosaccharide analysis, performed by thin-layer chromatography,
or more recently by mass spectrometry. The amino group from aspartylglucosamine also causes a
diagnostic ninhydrin peak on urine amino acid analysis. Lysosomes also contain an abundance of
proteases, and the deficiency of one of them, cathepsin K, results in pycnodysostosis, a disorder of
increased bone density [11]. Cathepsin K is a cysteine protease.
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Table 4
Lysosomal storage disorders with placental and/or fetal pathology
Disease
Niemann-Pick disease
Gaucher disease
Krabbe disease
Metachromatic leukodystrophy
Gangliosidoses
Glycogen storage disease type II
Glycogen storage disease type IV
Wolman disease
Cholesteryl ester storage disease
Mucopolysaccharidoses
Mucolipidoses
Sialidoses
Ceroid lipofuscinosis
Cystinosis
Sialic acid storage diseases

Placental Pathology

Fetal Pathology

+
±
–
–
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Fig. 2. Structure of sphingolipids. Sphingosine (top) plus a fatty acid forms ceramide (middle). Ceramide attached to a single
sugar forms a glucocerebroside (bottom). If ceramide is combined with a polysaccharide (complex sugar) with one or more
terminal N-acetylneuraminic acids, the result is a ganglioside.

Most of the remaining lysosomal storage diseases are glycosphingolipidoses. The sphingolipids
(Fig. 2) have a long-chain amino alcohol (sphingosine) that is combined with a fatty acid to produce
complex lipids (ceramides). When one sugar is added to a ceramide, a cerebroside results. When a
sulfate group is added to the sugar, the sphingolipid is a sulfatide. When a polysaccharide is added to the
ceramide, the product is a globoside, while the addition of one or more molecules of N-acetylneuraminic
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Fig. 3. Metabolic disorders characterized by sphingolipid storage and their enzyme deficiencies. Notice accumulation of
glucocerebroside in Gaucher disease, sphingomyelin in Niemann-Pick disease, galactocerebroside in Krabbe disease, sulfatide
in metachromatic leukodystrophy, globotriaosylceramide in Fabry disease, and GM2 ganglioside in Tay-Sachs disease. In
addition to GM2 ganglioside, patients with Sandhoff disease also accumulate globosides. GM1 ganglioside is stored in
generalized ␤-galactosidase deficiency, while the H antigen accumulates in fucosidosis.

acid to a globoside results in a ganglioside. N-acetylneuraminic acid (sialic acid) is always a terminal
sugar. The metabolic disorders characterized by sphingolipid storage and their enzyme deficiencies
are shown in Fig. 3. In these diseases (Table 5), a variety of lipids can be stored, including ceramides,
cerebroside and other ceramide hexosides, sulfatides, sphingomyelins, gangliosides and lipofuscins.
2.1. Niemann-Pick disease (acid sphingomyelinase deﬁciency)
The disease was first described by Albert Niemann in 1914 in a child with hepatosplenomegaly,
lymphadenopathy and progressive neurological deterioration who died before the age of 2 years [12].
Histopathological studies were later performed by Ludwig Pick, demonstrating the presence of foamy
cells, similar but not identical to those found in Gaucher disease [13]. In 1934, Ernst Klenk identified
the stored lipid as sphingomyelin [14]. In 1961, Crocker proposed classifying the disease into types
A, B, and C [15]. It wasn’t until 1966 that Roscoe Brady found a deficiency of acid sphyngomyelinase
in patients affected with Niemann-Pick disease type A and B, but not for type C [16].
The different types of Nieman-Pick disease (NPD) form a continuum of clinical severity [17]. The
most common and severe variant is type A, the acute neuronopathic form. Affected individuals, often of
Eastern European Jewish ancestry, present early in life. The skin can have a yellow-brown pigmentation,
lymph nodes are enlarged, and ocular manifestations (cherry-red macula and corneal opacifications)
are evident. Few patients survive beyond 4 years of age. The type B, or non-neuronopathic variant
(allelic with type A) resembles type A but spares the CNS. Affected children present at a later age with
isolated splenomegaly. In time, a more generalized visceral pattern of involvement is manifest, yet many
patients survive several decades. The term NPD type E was used in the past to designate patients with
an adult-onset, non-neuronopathic form of the disease with moderate hepatosplenomegaly; however,
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Table 5
Lysosomal lipid storage diseases
MIM No. Disease
257200

257220

230800

120900

Inheritance Deficiency Enzyme

Niemann-Pick A
(infantile cerebral
type)

AR

Niemann-Pick B
(juvenile noncerebral
type)
Niemann-Pick C
(subacute juvenile or
chronic neuronopathic
type)
Gaucher I (adult type)

AR

AR

AD

Clinicopathologic Features

Sphingomyelinase

Visceromegaly, cerebral deterioration,
rapid course; storage in
reticuloendothelial cells (foam cells),
hepatocytes, bone marrow, lungs,
peripheral and central neurons,
Ashkenazi Jews
Sphingomyelinase
Visceromegaly, lung infiltration;
storage cells and sea-blue histiocytes;
neurons not involved; milder
Deficient esterification of
Visceromegaly with storage cells,
exogenous cholesterol
cerebellar ataxia, seizures, psychotic
features; fibroblasts stain for
cholesterol
Glucocerebrosidase
Hepatosplenomegaly, osteoporosis,
(ß-glucosidase)
fractures; survival to sixth decade;
Gaucher cells are macrophages of
spleen, liver, nodes, thymus, marrow;
Ashkenazi Jews
Glucocerebrosidase
Visceral disease similar to type I,
(ß-glucosidase)
rapidly progressive cerebral damage
with brain macrophage cerebroside
storage, but only discrete neuronal
storage; short survival
Glucerebrosidase (ß-glucosidase) Both visceral and progressive
neurologic dysfunction; survival into
second or third decades; storage cells
as in Gaucher I and adventitia of
vessels of cortex and cerebral white
matter
Galactocerebrosidase
Onset 4–6 mo with rapid, severe
neurologic damage; storage “globoid
body” cells in central white matter

Gaucher IIA (infantile
cerebral type)

AR

Gaucher III

AR

245200

Krabbe, infantile type
short survival

AR

228000

Farber
Lipogranulomatosis
A. Early onset

AR

Ceramidase

B. Infantile type

AR

Ceramidase

C. Late onset

AR

Ceramidase

Neonatal type

AR

Ceramidase

Subcutaneous nodules, arthritis,
laryngeal, cerebral
Periarticular, no lung involvement, can
have normal intelligence
Survival into second decade, laryngeal,
joint but not lung involvement and
less cerebral dysfunction
Psychomotor delays, hepatomegaly,
debility
(Continued)
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Table 5
(Continued)

MIM No. Disease

Inheritance Deficiency Enzyme

Fabry disease

230500

GM1 gangliosidosis
type I (infantile)

AR

ß-Galactosidase

230600

GM1 gangliosidosis
type II (juvenile)
GM1 gangliosidosis
type III (adult)

AR

ß-Galactosidase

AR

ß-Galactosidase

GM2 gangliosidosis,
type I, infantile
Tay-Sachs
GM2 gangliosidosis,
juvenile Tay-Sachs
GM2 gangliosidosis,
Tay-Sachs AB form
GM2 gangliosidosis type
II, infantile Sandhoff
GM2 gangliosidosis,
juvenile Sandhoff
GM2 gangliosidosis,
chronic

AR

Hexosaminidase A (␣-unit
mutation)

AR

AR

Hexosaminidase A (␣-unit
mutation)
Hexosaminidase Activator
Protein (Saposin)
Hexosaminidases A and B

AR

Hexosaminidases A and B

AR

Hexosaminidases A and B

230650

272800

272800
272750
268800
230700
230710

XLR

␣-Galactosidase A

301500

AR

Clinicopathologic Features
Onset in males in first decade, later with
slower course in female
heterozygotes; nephrotic syndrome,
renal failure, cardiomyopathy (esp.
females), abdominal pain,
angiokeratomas of skin; storage in
glomerular and tubular epithelium,
cardiac myocytes, enteric and
brainstem/spinal cord neurons, blood
vessel walls
Survival 1-2 yr, abnormal facies,
skeletal changes (esp. vertebrae),
visceromegaly, cerebral deterioration;
ganglioside/mucopolysaccharide in
reticuloendothelial cells, liver,
glomerular and tubular epithelium,
pancreatic and mucoserous gland
epithelium, central and peripheral
neurons
Later onset; resembles type I
Adult onset; mental deterioration,
visual loss, myoclonic seizures,
angiokeratomas
Rapid dementia, blindness, macular
cherry-red spot; Ashkenazi Jews
Later onset than infantile form
Similar to infantile Tay-Sachs disease
Neuronal storage like that of Tay-Sachs
disease with modest visceral storage
Progressive dementia, ataxia
Spinocerebellar degeneration
resembling Friedreich ataxia, juvenile
spinal muscular atrophy resembling
Kugelberg-Welander disease, or like
amyotrophic lateral sclerosis. Chronic
Sandhoff disease can resemble
X-linked bulbospinal muscular
atrophy
(Continued)
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Table 5
(Continued)
MIM No. Disease
250100

272200

Inheritance Deficiency Enzyme

Clinicopathologic Features

Metachromatic
leukodystrophy,
infantile

AR

Metachromatic
leukodystrophy,
juvenile
Metachromatic
leukodystrophy, adult
Metachromatic
leukodystrophy
Multiple sulfatase
deficiency

AR

Arylsulfatase A (cerebroside
Onset ∼2 yr, survival to ∼5 yr;
sulfate sulfatase, or sulfatidase) hypotonia, muscle weakness, mental
deterioration, peripheral nerve
involvement; sulfatide storage in liver,
kidney, epithelium, rectal lamina
propia, central white matter, nerves
Arylsulfatase A
Onset 4–10 years; slower course

AR

Arylsulfatase A

AR

Saposin B (Sulfatase Activator
Protein 1)
Deficiency of 7 sulfatases due to Resembles metachromatic
inability to convert a cysteine to leukodystrophy with ichthyosis and
features of mucopolysaccharidosis;
2-amino 3-oxopropionic acid
variable severity

AR

Onset second decade; psychiatric
symptoms
Variable

this designation has fallen out of favor. An NPD type F form was proposed for a relatively benign form
characterized by the lack of neurological involvement and the presence of sea-blue histiocytosis [18];
this designation is also no longer in use.
In NPD B, a lipid pro-atherogenic profile has been described, with increased total and LDL cholesterol, increased triglycerides and low HDL cholesterol [19]. Mean splenic size is 12.7 multiples of
normal, while mean liver size is 1.91 multiples of normal. Thrombocytopenia is seen in 39%, and
leukopenia in 3%. There is stable elevation of liver transaminases and bilirubin, while pulmonary
function deteriorates over time [19]. The typical pattern of pulmonary involvement is that of restrictive
lung disease [20]. It can present with unexplained diffuse lipid pneumonia, even during adulthood
[21]. Joint and/or limb pain is seen in 39% of patients [20]. Short stature, low weight and delayed bone
age is also common [22]. There can be macular halo and/or cherry-red spots, but these do not portend
neurodegeneration [23].
In both NPD type A and B, storage material is found in reticuloendothelial cells, hepatocytes [24],
pulmonary macrophages, and syncytiotrophoblast and villus stromal cells [25]. Greenbaum et al.
[26] documented that total extracts of brain glycolipids in NPD type A contain increased levels of
glucosylceramide, dihexoside, and trihexoside, as well as GM2 . In type A, there is mostly neuronal,
less so vascular, sphingomyelin storage, while neutral glycolipid dominates in the vascular wall [27].
Hepatic storage of glycogen has been described in type B [28], and this has led to its misdiagnosis as
a glycogen storage disorder [29].
Schoenfeld et al. [25] reported placental ultrasonographic, biochemical, and histochemical studies in
human fetuses affected with NPD type A. Focal, opaque, strong echoes in placental tissue with thick and
irregular chorionic plates occur as early as 18.5 weeks in placentae of NPD fetuses [25]. Prenatal diagnosis has been achieved by measuring sphingomyelinase activity in cultured amniotic fluid cells [30].
The gene whose mutations are responsible for NPD types A and B is SMPD1 [17]. More than 180
different mutations have been reported [31], and sequencing identifies a mutation in 95% of new cases.
Three mutations—p.Arg498Leu, p.Leu304Pro, and p.Phe333Serfs*52—account for more than 90%
of the mutant alleles in Ashkenazi Jewish patients [17]. Unlike NPD type A, NPD type B does not
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occur more frequently in the Ashkenazi Jewish population; more than half of patients reported with
NPD type B are of Turkish, Arabic, or North African descent [32]. A single deletion, p.Arg610del,
accounts for almost 90% of the mutant alleles in type B patients from North Africa [33]. Some degree
of genotype-phenotype correlation has been identified [19, 32]. The prevalence of NPD types A and
B combined is about 1 in 250,000 [17].
The diagnosis of types A and B NPD can be made readily by enzymatic determination of sphingomyelinase activity in cell and/or tissue extracts. However, heterozygote detection is unreliable by
enzyme assay and requires molecular studies. Prenatal diagnosis has been accomplished by enzymatic
and/or molecular analyses of cultured amniocytes or chorionic villi.
Although there is no specific therapy for type A or B NPD, bone marrow transplantation has corrected
the metabolic defect and reduced the liver and spleen size. However, there has been no effect on the
neurological status, and thus it is reserved for patients with NPD type B [34–36]. A recombinant human
acid sphingomyelinase (olipudase alpha) is currently in clinical trials in the form of intravenous enzyme
replacement therapy [37]. Retrovirus-mediated gene transfer corrects the metabolic defect in cultured
NPD fibroblasts, raising the possibility of future treatment of type B NPD by somatic gene therapy [38].
Pathologically, light (LM) and electron microscopic (EM) changes are similar in Niemann-Pick types
A and B. The storage cell ranges in diameter from 20 to 90 m, and the cytoplasm is filled with lipid
droplets that impart a “soap bubble” appearance with the nucleus displaced to the periphery (Fig. 4).
Cells in the viscera, predominantly liver (Fig. 5), spleen (Fig. 6), lung alveoli (Fig. 7), and ganglion cells
of the myenteric plexus (Fig. 8) may contain lipofuscin pigment, sphingomyelin, and lesser quantities
A

B

Fig. 4. Niemann-Pick disease. (A) A sea-blue histiocyte is present in the marrow. These cells are predominantly seen in types
C and F. (B) A histiocyte in the bone marrow has a “soap-bubble” appearance and measures 60 to 80 m in diameter.

Fig. 5. Niemann-Pick disease. Vacuolated storage cells are present in Kupffer cells within the sinusoids of the liver.
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Figs. 6–8. Niemann-Pick disease. The splenic sinusoids are filled with distended vacuolated histiocytes; (7) Niemann-Pick
disease. The alveoli of the lungs are filled with storage cells; (8) Niemann-Pick disease. The ganglion cells of the myenteric
plexus of the gastrointestinal tract are distended with storage material (Luxol fast blue stain).
Table 6
Histochemical profile in Niemann-Pick disease

Luxol fast blue
PAS
After NaOH
After Kbr
Sudan black B
Oil red O
After hot acetone
After cold acetone
OTAN
NaOH-OTAN∗
Ferric hematoxylin
After NaOH
Schultze reaction for cholesterol
AZO dye reaction for acid phosphatase
Autofluorescence

Neural Tissue

Visceral Organs

Bone Marrow

+++
++
++
++
++
+
+
+
+++
+++
++
++
+
++
+++

++
+++
+++
+++
++
+
+
+
+++
+++
++++
++++
++
++
++

++
+++
+++
+++
++
+
+
+
+++
+++
++++
++++
++
++
+

PAS, periodic acid-Schiff; OTAN, osmium tetroxide ␣-napthylamine. ∗ The most specific histochemical
stain for sphingomyelin.

of cholesterol and gangliosides [11]. Storage is also present in the macrophages of the lung. The
histopathological correlate of the cherry-red spot is that of ballooned, lipid-laden retinal ganglion cells
[39]. The stored material is birefringent when examined under a polarized filter, unless lipid solvents
have been used. The histochemical staining reactions confirm the presence of a complex phospholipid
(Table 6). Differential staining characteristics of Gaucher, NPD, and the gangliosidoses are shown in
Table 7. The NPD cells stain positively with oil red O, Sudan black (Fig. 9), Nile blue sulfate, and
Luxol fast blue and the OTAN (osmium tetroxide ␣-naphthyl-amine) reaction after pretreatment with
NaOH. The ultrastructural appearance of the lipid inclusions consists of concentrically laminated,
myelin-like figures with a periodicity of approximately 50 Å, resembling membranous cytosomes and
other pleomorphic lipid profiles. In the viscera, lipid inclusions are frequently membrane-bound and
contain stacked membranes, concentrically laminated membranes, and pleomorphic profiles with both
electron-dense and electron-lucent cores (Fig. 10) [40–43]. Cultured fibroblasts have similar inclusions
and cultured amniotic cells contain storage material (Fig. 11).
The brain is large (Fig. 12) during the first 6 to 12 months of life because of the accumulation of
sphingolipids and gangliosides with membranous concentric bodies (MCBs) (Fig. 13). The neurons
are distended (Fig. 14). Later the brain becomes atrophic with enlargement of the ventricles (Fig. 15).
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Table 7
Histochemical staining of three types of lysosomal lipidoses

PAS
PAS-amylase
Schultz cholesterol technique
Oil red O
Oil red O after cold acetone
extraction
Oil red O after hot acetone
extraction
Oil red O after pyrimidine
extraction
Luxol-fast blue
OTAN
NaOH-OTAN
Alcian blue
Acid phosphatase
Cells involved
Biopsy tissues of choice

Gaucher Disease

Niemann-Pick Disease

Gangliosidoses GM1 and
GM2 (Types 1 and 2)

+++
+++
0
+ to ++
+ to ++

0 to +
0 to +
++
+++
+++

++ to +++
+++
–
++
++

0

+++

+ to ++

0

0

0

0
0
0
Adult 0 to +/infantile ++
++
RE cells (neuron in infantile)
Spleen, marrow

+++
+++
+++
+
0 to +
RE cells (neuron in infantile)
Marrow or spleen

++
++
0 to +
0
++
Neurons
Nerve cells

PAS, periodic acid-Schiff; OTAN, osmium tetroxide ␣-napthylamine; RE, reticuloendothelial.

9

10

11

Figs. 9–11. Niemann-Pick disease. Ganglion cells of the myenteric plexus stain strongly for lipid with Sudan black B
stain; (10) Niemann-Pick disease. Electron micrograph of a storage cell in the spleen contains pleomorphic lipid profiles;
(11) Niemann-Pick disease. Electron micrograph of a cultured fibroblast contains pleomorphic lipid profiles and electrondense deposits.
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13

14

Figs. 12–14. Niemann-Pick disease. The brain is large during the first years of life due to the accumulation of storage
material; (13) Niemann-Pick disease. Electron micrograph of a neuron shows membranous concentric bodies of gangliosides;
(14) Niemann-Pick disease. Microscopic section of the brain shows large distended neurons.
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Fig. 15. Niemann-Pick disease. A child 2 years of age. The brain is atrophic with enlargement of the ventricles.

The placenta may be enlarged, and there is vacuolation and histochemical evidence of storage in
syncytiotrophoblast and villus stromal cells [25]
Many of the lipids that accumulate in NPD are not substrates for sphingomyelinase, including
glucocerebroside, GM2 , and GM3 . The predominant lipid in NPD is phospholipid, but sphingomyelin,
cholesterol, bis-(monoacylglycerol) phosphate, and glycosphingolipid also accumulate.
2.2. Niemann-Pick disease type C
Niemann-Pick disease type C (NP-C) is not a primary acid sphingomyelinase deficiency, but was
given its moniker because sphingomyelinase activity is secondarily reduced. NP-C is an autosomal
recessive lipidosis distinguished by a unique error in cellular trafficking of cholesterol that is associated
with lysosomal accumulation of unesterified cholesterol. Most patients with NP-C have progressive
neurologic disease, and hepatic damage is prominent in certain cases [44]. There is lysosomal accumulation of low-density lipoprotein (LDL)-derived cholesterol, and glycolipid is stored in neurons. At
least some cases of lactosylceramidosis, previously thought to be a distinct condition, are now known
to be caused by NP-C [45].
There are two known genes in which biallelic mutations result in NP-C. NPC1, responsible for 90% of
cases of the disease, contains 25 exons and encodes a 1278 amino acid protein. More than 390 different
mutations have been described. The NPC1 protein has sequence similarity to the morphogen receptor
PATCHED and the putative sterol-sensing regions of SREBP cleavage-activating protein (SCAP) and
ß-hydroxy-ß-methylglutaryl coenzyme A reductase [46]. Niemann-Pick type D, or the Nova-Scotian
variant, was found to be caused by a specific mutation in NPC1, and thus this designation is no longer
in use [47]. NPC2, with 5 exons encoding a 132-amino acid glycoprotein, accounts for 4% of cases
of NP-C. Approximately 20 mutations have been found in the NPC2 gene [48]. Genotype-phenotype
correlations have been described for both the NPC1 [49] and NPC2 genes [50].
The clinical manifestations of NP-C are heterogeneous. The classic phenotype is characterized by
variable hepatosplenomegaly, vertical supranuclear ophthalmoplegia, progressive ataxia, dystonia, and
other neurologic symptoms like cataplexia, ataxia, myoclonus, seizures, and loss of previously acquired
speech at about 5 years of age. Organomegaly is less pronounced than in types A and B, and may be
lacking altogether. Affected children present in childhood and die in the second decade. Neonates
can present with ascites and meconium ileus and have developed biliary atresia or, more commonly,
a neonatal hepatitis syndrome [51]. Other phenotypes include early infantile onset with hypotonia
and delayed motor development, and adult variants where psychosis and dementia predominate [52].
Patients with NP-C2 typically have marked pulmonary involvement, leading to respiratory failure and
early death [50].
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The diagnosis of NP-C now relies upon molecular testing; filipin-cholesterol staining in cultured
fibroblasts during LDL uptake can also be performed by some laboratories. There is considerable
variability in the degree of impairment of cholesterol esterification in NP-C. About 15% of patients
show a “variant” biochemical phenotype, with an intermediate-to-normal rate of cholesterol esterification, and a less distinctive filipin staining [53]. Elevated levels of oxysterols in plasma–in particular
cholestane-3␤,5␣,6␤-triol and 7-ketocholesterol–as measured by LC-MS/MS can also be used as a
diagnostic tool, both in patients with NP-C1 [54] and NP-C2 [48]. Antenatal diagnosis can be achieved
through molecular diagnostics. NP-C is estimated to be as frequent as NP-A and NP-B combined, with
a prevalence of about 1 in 150,000 [44].
Various drug regimens lower hepatic cholesterol levels in NP-C. It is not known if such treatment
influences neurologic progression [55]; one drug currently in clinical trials is 2-hydroxypropyl-␤cyclodextrin [56]. Symptomatic treatment of seizures, dystonia, and cataplexy is effective in many
patients with NP-C. Bone marrow transplantation has been performed in patients with NP-C2, leading
to resolution of the lung disease, although it can be associated with a severe “graft-versus-substrate”
effect requiring intense immunosuppression until resolution [57].
The pathology of NP-C includes the presence of foam cells or sea-blue histiocytes in many tissues.
Such cells are not specific for NP-C and may be absent in cases lacking visceromegaly. Neuronal
storage with cytoplasmic ballooning and a variety of inclusions is present throughout the nervous
system. Meganeurites and axonal spheroids are also seen. Neurofibrillary tangles and neuropil threads
composed of tau protein can be detected by Bielschowsky stain or immunohistochemistry [58, 59]. The
former vary in shape and size, unlike the torch-like or flame-shaped inclusions seen in patients with
Alzheimer’s disease [59]. Characteristic inclusions may be identified in skin and conjunctival biopsies
[60–62]. Unesterified cholesterol, sphingomyelin, phospholipids, and glycolipids are stored in excess
in the liver and spleen, while only glycolipids are elevated in the brain. Marked storage can be seen as
early as in a 20-week fetus [63]. Partial sphingomyelinase deficiency, observed only in cultured cells,
represents a variable, secondary consequence of lysosomal cholesterol esterification.
2.3. Gaucher disease
In 1882, while just a 27-year-old intern, Phillippe Gaucher presented his MD thesis, in which he
described a patient with splenomegaly due to infiltration by abnormal cells. He had speculated that
this was a primary splenic epithelioma [64]. Similar cases were subsequently published, but it wasn’t
until the first decade of the twentieth century that the eponym Gaucher disease started being used [65].
The underlying enzyme deficiency was identified by Roscoe Brady in 1965 [66].
Gaucher disease, the most common of the lysosomal storage diseases, is an autosomal recessive disorder due to deficiency of glucocerebrosidase (acid ␤-glucosidase), which converts glucocerebroside
to ceramide and glucose [67, 68]. As a consequence of this defect, glucocerebroside (GL1), an intermediate in the catabolism of globoid and gangliosides, accumulates in the reticuloendothlial system
(Fig. 16).
The gene encoding acid ␤-glucosidase, GBA, resides on chromosome 1q21-q22 and has 11 exons;
more than 400 mutations have been described [31]. Most of the Gaucher disease alleles are missense
mutations that lead to the synthesis of acid ␤-glucosidases with decreased catalytic function and/or
stability. Nonsense and frameshift mutations have also been reported. Four mutations, N370S, 84GG,
IVS2+1G>A, and L444P, are responsible for 90% of the mutant alleles in type 1 Gaucher disease in
Ashkenazi Jews and over 50% in non-Jewish patients with type 1 Gaucher disease [67]. The clinical
manifestations of Gaucher disease are relatively mild in N370S homozygotes, and do not include
neurological findings. Homozygotes for L444P, a common mutation also encountered in a geographical
isolate in Northern Sweden, generally present with type 3 disease of variable severity.
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Fig. 16. (A) The pathophysiology of Gaucher disease. It should be noted that this macrophage-centric view of the disease
has recently been called into question, since it does not explain certain aspects of the disease such as the predisposition to
malignancy, osteoporosis or Parkinson disease (108). (B) The enzymatic defect in Gaucher disease. (From Gaucher Disease
Diagnosis Evaluation and Treatment, Genzyme Therapeutics, Parsipanny, NJ; with permission.)

A pseudogene that has maintained a high degree of homology is located approximately 16 kb downstream of the active gene. Several mutations appear to have originated from pseudogene sequences;
some appear as fusion genes between the gene and pseudogene [69], or as part of other recombinant
alleles that contain varying lengths of additional pseudogene sequences [70].
Three types of Gaucher disease (Table 8) reflect the degree of ␤-glucocerebrosidase deficiency [67,
68], although hepatosplenomegaly, bone lesions, and occasional involvement of lungs and other organs
occur in all forms of Gaucher disease. Type 1, by far the most common form, occurs in the Ashkenazi
Jewish population with a frequency of approximately 1 in 855 [67], and is distinguished from types
2 and 3 disease by the lack of primary CNS involvement, with the exception of Parkinsonism in
later life. The average age at diagnosis for type 1 is 30–40 years, although patients are commonly
diagnosed in childhood or adolescence. The chronic manifestations of the disease vary considerably
in severity, and Gaucher disease does not always breed true [71]. Milder patients present as adults, and
a significant number of individuals with type 1 disease never come to medical attention [72]. The systemic manifestations include hepatosplenomegaly (Fig. 17), thrombocytopenia, anemia, leucopenia,
osseous abnormalities, delayed sexual maturation and growth retardation. A radiographic finding of
an Erlenmeyer flask deformity of the distal ends of the femur (Fig. 18) is common in Gaucher disease
[73]. Renal involvement, pulmonary hypertension, and cardiac abnormalities are less frequent. Patients
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Table 8
Gaucher disease: Clinical types

Clinical Features

Type I-Chronic, nonneuronopathic

Type II-Acute,
neuronopathic

Type III-Subacute,
neuronopathic

Age at presentation
Splenomegaly
Hepatomegaly
Skeletal Disease
Primary CNS Disease
Lifespan (typically)
Ethnicity
Frequency

Childhood/Adulthood
+ −→ +++
+ −→ +++
– −→+++
Absent
6–80+ years
Panethnic; Ashkenazi Jews
1/450–1/1000 Ashkenazi Jewish
1/40000 – 1/2000000 General Population

Infancy
++
++
–
+++
<2 years
Panethnic
<1/100000

Childhood/Adulthood
+ −→ +++
+ −→ +++
++ −→ +++
+ −→ +++
2–60 years
Panethnic; Norbottnian Swedes
<1/50000

Adapted from Gaucher Disease: Diagnosis Evaluation and Treatment, Genzyme Therapeutics, with permission. (Genzyme Therapeutics, 100 Lackawanna Ave., Parsippany, NJ 07054; Ph: 800/745-4447, ext. 7664; Fax: 617/374-7357;
www.genzyme.com/prodserv/welcome.htm.).
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Figs. 17, 18. Gaucher disease type I. A child 10 years of age showing marked distension of the abdomen due to massive
splenomegaly. The spleen was surgically removed and weighed 10 kg; (18) Gaucher disease. Radiograph of lower extremities
showing Erlenmeyer flask deformity of the distal ends of the femur.

with type 1 disease can have a normal life expectancy, although an increased risk of malignancy,
especially multiple myeloma and hepatocellular carcinoma, has occurred in late adulthood [74].
Type 2 Gaucher disease, the acute neuronopathic form, has an early onset with severe CNS involvement and death usually within the first 2 years of life. It has no ethnic predilection. There are severe
neurologic complications and signs of cranial nerve nuclei and extrapyramidal tract involvement can
appear at birth or by 6 months of age. Although neuronal cerebroside storage is not a feature, the
brain is the site of extensive neuronal cell death, reactive gliosis, and the perivascular accumulation
of Gaucher cells. Clinical manifestations include strabismus, oculomotor apraxia, trismus, dysphagia, retroflexion of the head, cortical thumbs and limb rigidity, increased deep tendon reflexes with a
positive Babinski sign, pulmonary infections, and failure to thrive. Some patients have seizures. The
presence of hepatosplenomegaly in an infant with oculomotor abnormalities and retroflexion of the
neck is highly suggestive of type 2 Gaucher disease. Estimates of the incidence of type 2 Gaucher
disease range between approximately 1 in 100,000 and 1 in 500,000 births [75].
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Table 9
Bone radiographic findings in Gaucher disease
• Femoral head and femoral shaft are most frequently involved
• The “Erlenmeyer flask” deformity of the distal femur is a common finding
• Vertebral bodies, humeral heads, and the ischium may be involved
• Vertebral bodies can collapse, creating a gibbus and spinal cord compression
• Marrow replacement occurs
• Osteopenia can lead to fractures
• Bone lesions display focal deposits of Gaucher cells
• Lytic lesions may simulate bone tumors and may require biopsy

Therapy of type 2 Gaucher disease has primarily been supportive.
A variant of type 2 Gaucher disease also displays congenital ichthyosis and/or hydrops, sometimes
with joint abnormalities [76].
Patients with type 3 (subacute neuropathic) Gaucher disease have neurologic symptoms with a later
onset and a more chronic course than that observed in type 2 disease. The median age of onset is
one year, with considerable variability. The most common neurologic manifestation is the slowing
and looping of the horizontal saccadic eye movements. Some patients may develop ataxia, spasticity,
akinetic and myoclonic seizures, and variable degrees of dementia while others only have eye movement abnormalities or learning disabilities. A variant known as type 3c presents with cardiovascular
calcifications, including aortic valve, mitral valve, and ascending aorta calcifications. It can also be
accompanied by corneal clouding, hydrocephalus and supranuclear ophthalmoplegia. Gaucher disease
type 3c is caused by homozygous D409H mutations [77–79].
Recently, Gaucher disease has been associated with Parkinsonism, and even heterozygosity for GBA
mutations carries an increased risk for it [80–82]. The penetrance of Parkinsonism in carriers increases
with age [83, 84]. In fact, mutations in GBA are now the most common known genetic risk factor
for Parkinson disease. However, the majority of adults with Gaucher disease never develop Parkinson
disease.
Skeletal manifestations are a major source of disability in Gaucher disease, affecting over 80% of
symptomatic patients and resulting in serious complications in many (Table 9). Early assessment and
routine monitoring of skeletal involvement, even in asymptomatic patients, are important since changes
in bone are progressive and in some cases, may be reversed by enzyme replacement therapy. Several
imaging modalities are currently used to evaluate bone disease: plain radiography, magnetic resonance
imaging (MRI), MR quantitative chemical-shift imaging (QCSI), computed tomography (CT), and
nuclear scans.
The diagnosis of Gaucher disease (Table 10) should be considered in any patient with unexplained
splenomegaly. The diagnosis is made by finding deficient glucocerebrosidase activity in leukocytes,
dried blood spots, or fibroblasts, i.e., 0–35% of normal depending upon the laboratory [67, 68]. Reliable
detection of carriers by enzyme assay is more difficult, as there is considerable overlap between the
glucocerebrosidase activity of normal individuals and that of heterozygotes, with up to 20% of obligate
heterozygotes possessing enzyme activity in the normal range [33]. Enzyme assay for heterozygote
detection is being superseded by molecular techniques that can efficiently detect heterozygotes once
the mutations of an affected patient are known. More than 90% of mutations in Ashkenazi Jews can
be detected by screening for the most common mutations, and approximately 50% of the mutations
in non-Jewish populations can be detected in this manner. However, the exact percentage depends
upon the number of common mutations being screened, and upon the population’s ethnicity. In utero
diagnosis of Gaucher disease can be made by applying enzyme assay techniques or mutation analysis
to cultured amniocytes [24].

20

C.R. Ferreira and W.A. Gahl / Lysosomal storage diseases
Table 10
Diagnosis of Gaucher disease

• Glucocerebrosidase assay (on leukocytes, DBS, fibroblasts, amniocytes, chorionic villi) is
the gold standard.
• The assay uses a fluorescent substrate; less than 30% activity makes the diagnosis.
• Heterozygotes average 50% of normal ␤-glucocerebrosidase activity.
• 20% of carriers demonstrate enzyme activity in the normal range.
• DNA screens for selected GBA mutations may detect common mutations but can lead
to ambiguous results when variants of unknown significance are found.
• DNA analysis is better for heterozygotes if the mutation is known.
Associated Findings
• Elevated serum acid phosphatase, chitotriosidase and angiotensin-converting enzyme
• Elevated plasma ferritin levels are commonly seen
• Decreased plasma cholesterol levels in unsplenectomized patients

Table 11
Supportive therapy modalities
Bone Crises
• Intravenous hydration and administration of narcotics
• Cultures and antibiotics for osteomyelitis if indicated
• Orthopedic procedures (joint replacement)
• Analgesics for bone pain
• Restriction of activity
Hypersplenism
• Rarely, splenectomy may be indicated for severe thrombocytopenia and anemia
• Transfusions
Supplemental treatment
• Oral bisphosphonates and vitamin D

The treatment of Gaucher disease can be divided into therapy directed at the basic defect and supportive care. Directed therapy [67] includes enzyme replacement, which has been extremely successful
for systemic manifestations, substrate reduction with miglustat or eliglustat, and bone marrow transplantation [85, 86]. Cell and gene therapy have been effective in a mouse model [87, 88]. Recombinant
human glucocerebrosidase is modified for enhanced uptake by macrophages. The enzyme is given
by periodic intravenous infusions according to various dosing schedules, and is well tolerated albeit
extremely expensive with infusions costing several hundred thousand dollars per patient per year.
Approximately 15% of patients develop antibodies, depending upon the preparation, but most are not
neutralizing. Some individuals can develop urticaria and pruritus related to the infusions, treatable with
antihistamines. Enzyme replacement improves quality of life, reduces hepatomegaly, hypersplenism,
anemia, thrombocytopenia, and secondary bone marrow failure [67]. It is also reported to reduce the
rate of bone loss and bone crises [89] and to stabilize myelofibrosis and cirrhosis. However, no neurological benefit has been proven. Supportive therapy for Gaucher disease involves treating bone crises,
the hypersplenism and its consequences, and chronic pain. Table 11 lists some supportive measures.
In type 2 Gaucher disease, it appears that the pathology begins in the placenta and fetus. The placenta
may be edematous, and storage material has been found within Hofbauer (placental histiocytes) cells
and in cells within intravillus vessels [90]. Fetuses at 17 and 20 weeks’ gestation also have storage
cells, particularly in the liver and spleen, but do not demonstrate neuropathologic changes. In contrast
[91], a 26-week-gestation fetus has shown extensive neuronal loss and gliosis in those areas with the
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Fig. 19. Gaucher disease. (A) Microscopic section of the spleen. The sinusoids are filled with large distended storage cells. (B)
The bone marrow contains a large Gaucher cell with cytoplasmic striations with typical “crinkled tissue paper” appearance.

most mature neurons, i.e., spinal cord, brainstem, thalamus, and basal ganglia [91]. The fetal Gaucher
cell may not have well-delineated striations as it does in the mature patient. Instead, it may appear
foamy, and yet tubular cytosomes are still identifiable by EM. The association of Gaucher disease and
hydrops fetalis has been observed in several cases [70, 90–92]. Gaucher cells, present in abundance in
hepatic sinusoids and filling the lumens of hepatic veins, may contribute to the fetal ascites.
Postnatal pathology in Gaucher disease is characterized by the accumulation of glucocerebroside in
histiocytes of the reticuloendothelial system including spleen (Fig. 19A), lymph nodes, bone marrow,
and Kupffer cells of the liver (Table 12). Late in the disease, portal fibrosis may progress to cirrhosis.
The pathognomonic feature is the Gaucher cell–a large vacuolated histocyte seen in the bone marrow,
liver, spleen, and lymph nodes with striated cytoplasm (Fig. 19B) best demonstrated with trichrome
or aldehyde fuchsin staining [93]. Gaucher cells are 20 to 100 m in size and have a small eccentric
nucleus with a “wrinkled tissue paper” or “crumpled silk” appearance to their cytoplasm. They stain
positively with the periodic acid-Schiff (PAS) reagent. Most give a strongly positive reaction for
acid phosphatase. The appearance of the cell is distinctive enough to permit its use as a diagnostic
criterion but bone marrow biopsy should not be used as a method of diagnosis. The macrophages of
other sphingolipidoses, such as Niemann-Pick disease, possess multiple intracytoplasmic droplets of
uniform size, giving them a foamy rather than crumpled silk appearance. Cells resembling Gaucher cells
may be found in multiple myeloma, leukemias, thalassemia, and congenital dyserythropoietic anemia.
However, Gaucher cells can be distinguished from these so-called pseudo-Gaucher cells by their much
stronger expression of HLA-DR on immunohistochemistry [94]. Erythrophagocytosis by Gaucher
cells is common, and hemosiderin is frequently found in the cells. Ultrastructurally, the Gaucher cell
cytoplasm is packed with rod-shaped inclusions bound by a single membrane. The inclusions contain
tubules that run parallel to their long axes and are branched. The tubules have a clockwise spiral
(Fig. 20). This membrane-bound cytoplasmic vacuole, containing tubular structures, is known as the
“Gaucher body”. The iron dispersed in the cells is seen by EM and stains positively by the Prussian blue
stain; individual micelles of ferritin are present [95]. In the bone marrow, large collections of Gaucher
cells replace the marrow cells. In the liver [96], the accumulation of the glycolipid occurs within the
Kupffer cells and the hepatocytes are spared. In the lungs, alveolar involvement by Gaucher disease
can occur, but rarely. Gaucher cells are also frequently observed in both the cortical and medullary
portions of the thymus and adrenal gland. Lymph nodes and the lamina propria of the gastrointestinal
tract may be involved [97]. Lipid analyses of spleens and livers from patients with Gaucher disease
have exhibited 20 to 100-fold increases in glucocerebroside [97, 98]. However, the quantity of lipid
stored does not account for the extreme organomegaly seen.
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Table 12
Pathologic findings in Gaucher disease

SPLEEN-Gross
• May be more than 20 times the normal size and have hard texture and surface nodules
• Range from deep red (normal) to purple (extramedullary hematopoiesis) to yellow (old infarcts)
SPLEEN-Microscopic
• Accumulation of Gaucher cells
• Fibrosis
• Infarcts that account for up to 25%–50% of a massively enlarged spleen
LIVER-Gross
• Yellow-brown discoloration
• Areas of extramedullary hematopoiesis
• Nodules may be present in areas of infarction or Gaucher cell infiltration
LIVER-Microscopic
• Gaucher cells in the sinusoids and in parenchymal nodules
• Fibrosis may be present
CENTRAL NERVOUS SYSTEM (CNS)
• Spinal cord compression secondary to vertebral collapse
• Bleeding due to coagulopathies can cause CNS damage
• In type 2 Gaucher disease, Gaucher cells can be seen within the brain parenchyma, especially within occipital lobes
including the Virchow Robin spaces of the cortex, deep white matter, gray matter of the thalamus and subependymal
tissue of the pons and medulla
• Neuronophagia is prominent in the cortex, midbrain nuclei, basal ganglia, brainstem, and dentate nucleus
• Neuronal loss is widespread in type 2; the dentate nucleus is severely involved as well as hipocampal layers CA2-4.
• PAS-positive inclusions may be seen
HEMATOLOGIC FINDINGS
• Bleeding secondary to thrombocytopenia, factor XI or factor IX deficiency
• Thrombocytopenia due to splenic sequestration; responds to splenectomy
• Anemia (normocytic, normochromic); usually mild, with hemoglobin > 8 mg/dL but can be severe
• Marrow replacement
• Leukopenia
• Acquired von Willebrand factor deficiency
• Gaucher cells in marrow
• Increased iron storage
• Increased incidence of multiple myeloma
• Necrosis, yellow discolored areas of bone marrow replacement
LUNG
• Rarely, pulmonary failure may result from infiltration by Gaucher cells, or right to left shunting
• Pathology can be interstitial infiltration, alveolar consolidation, or capillary plugging by Gaucher cells
• Pulmonary hypertension can develop
OTHER PATHOLOGIC FINDINGS
• Osteoporosis
• Lymph node involved with Gaucher cells
• Thymus, Peyer patches, adenoids, and tonsils can be involved
• Brown masses of Gaucher cells have been reported in the eye at the corneoscleral limbus
• Gaucher cells have been found in a colonic polyp and the maxillary sinus
• Type 2 patient autopsies show severe infiltration of the adrenal gland
• Rare Gaucher cells have been found in the renal glomerular tufts and renal interstitium
• Tubular inclusions have been seen in endothelial cells lining glomerular and interstitial capillaries
(Continued)
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Table 12
(Continued)
BIOCHEMICAL ABNORMALITIES
• Marked deficiency of lysosomal glucocerebrosidase in leukocytes, fibroblasts, or tissues
• Elevated plasma tartrate-resistant acid phosphatase
• Decreased or elevated plasma cholesterol
• Increased plasma angiotensin converting enzyme
• Increased plasma chitotriosidase
• Increased plasma glucocerebroside and glucosylsphingosine

Fig. 20. Gaucher disease. Electron micrograph of a Gaucher cell. (A). Branching tubular profiles are present in a lysosome.
(B) High magnification of tubule with clockwise spiral in Gaucher disease lysosome.

The systemic pathologic findings in type 2 Gaucher disease resemble those of type 1. Gaucher
cells are especially abundant in the red pulp of the spleen, the sinusoids of the liver, the alveolar
capillaries, lymph nodes, and bone marrow. The spleen is enlarged with fibrosis, infarcts, and nodules
related to vascular malformation of the red pulp or extramedullary hematopoiesis [97]. The gross
appearance of the brains of patients with type 2 Gaucher disease is usually not altered. Microscopically,
however, Gaucher cells can be observed both perivascularly in the Virchow-Robin spaces and scattered
individually or in clumps within the cerebral gray matter [97]. Neuronophagia and neuronal loss in the
thalamus, basal ganglia, brainstem, cerebellum, and spinal cord can also be observed [97, 99, 100].
The lesions described are small and focal.
Glucosylsphingosine (lyso-GL1) is also hydrolyzed by the enzyme glucocerebrosidase and is elevated in brains from patients with neuronopathic Gaucher disease [101]. Levels of glucosylsphingosine
are also elevated in spleen and liver in patients with all three types of Gaucher disease. It has been
postulated that derivatives of glycosphingolipids are potent inhibitors of protein kinase C activity
[102] and could disrupt neuronal activity by interfering with signal transduction. The accumulation of
substrates such as GL1 and lyso-GL1 is known to cause immune dysregulation [103, 104].
Glucocerebrosidase also plays a role in skin barrier function. Rare patients with type 2 Gaucher
disease have been described with congenital ichthyosis. While light microscopic analysis of skin
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from patients with type 1 and type 3 Gaucher disease is normal, skin samples from patients with
type 2 Gaucher disease reveal dense hyperkeratosis, epidermal hyperplasia, and inflammation [105].
The ultrastructure of the epidermis from type 2 Gaucher patients, with or without clinical evidence of
ichthyosis, shows abnormal arrays of loosely packed lamellar bodies in the stratum corneum [105–107].
2.4. Krabbe disease (globoid cell leukodystrophy)
The disease was first described by the Danish neurologist Knud Haraldsen Krabbe in 1916 [109],
with the enzymatic defect identified in 1970 [110]. Krabbe disease is an autosomal recessive disorder caused by the deficiency of galactocerebrosidase, the lysosomal enzyme responsible for the
degradation of galactocerebroside to ceramide and galactose. As a consequence, galactosylceramide
accumulates in the peripheral and central nervous systems. Galactocerebroside (galactosylceramide) is
a sphingoglycolipid consisting of sphingosine, fatty acid, and galactose, and is normally present almost
exclusively in the myelin sheath [111]. In Krabbe disease, galactocerebroside does not accumulate in
the white matter but is catabolized through an alternative pathway that yields pyschosine (galactosphingosine), which is toxic to oligodendrocytes. Galactocerebroside, however, does accumulate in cerebral
macrophages that fuse to form multinucleated, PAS-positive globoid cells. The galactocerebrosidase
gene, GALC, has 17 exons encoding 669 amino acids [112]. More than 130 disease-causing mutations
have been reported [31]. The prevalence of the disease is estimated at around 1 in 100,000 births [112].
Krabbe disease usually presents between 3 and 6 months of age after a normal neonatal period with a
rapidly progressive course involving irritability, hypersensitivity to external stimuli, and severe mental
and motor deterioration [111, 112]. Patients rarely survive beyond 2 years. Clinical manifestations are
limited to the nervous system with prominent long-tract signs. Hypertonicity with hyperactive reflexes
present in the early stages, but patients later become flaccid and hypotonic. Blindness, deafness, and
seizures are common. Peripheral neuropathy is almost always detectable. The clinical picture of the
classic infantile form is relatively uniform, but atypical or late-onset forms of the disease have more
variable, albeit progressive, neurological courses. Pes cavus, optic disc pallor, progressive spastic
tetraparesis and moderate CSF protein elevation is common in late-onset forms [113]. Late-onset
Krabbe disease has been misdiagnosed as motor neuron disease [114], hereditary spastic paraplegia
[115], multiple sclerosis and Charcot-Marie-Tooth disease [116]. Aside from the leukodystrophy seen
on MRI, patients with Krabbe disease can have intracranial calcifications, better assessed by CT
[117–119].
The diagnosis of Krabbe disease can be made by assay of galactosylceramidase in leukocytes or
cultured fibroblasts, using appropriate natural glycolipid substrates. This method can also identify
heterozygous carriers. Intrauterine diagnosis of affected fetuses by galactosylceramidase assays on
amniotic fluid cells or biopsied chorionic villi has been performed [111]. Umbilical cord blood transplantation in presymptomatic newborns with the infantile form of the disease allowed progressive
myelin deposition and developmental gains, while transplantation after the initiation of symptoms provides no benefits [120]. Stem cell transplantation has been performed in individuals with the late-onset
form of the disease as late as 16 years after initiation of symptoms, still allowing clinical improvement
and halting progression of demyelination on serial neuroimaging [121]. Other modalities under investigation include enzyme replacement therapy, neural stem cell transplantation, chemical chaperone
therapy, and substrate reduction [112].
The pathology of Krabbe disease (Table 13) is confined to the CNS and is characterized by cerebral
atrophy, loss of myelin, gliosis, and globoid cells. The globoid cells are multinucleated microglial
macrophages distended with galactocerebroside storage material. There is diffuse demyelination of
the white matter (Fig. 21A) and numerous calcifications. An intense gliosis is present in the cortex,
basal ganglia, and especially around the perivascular spaces of the white matter. The perivascular

C.R. Ferreira and W.A. Gahl / Lysosomal storage diseases

25

Table 13
Krabbe disease: Pathologic findings
• Widespread myelin loss throughout the white matter with fibrillary gliosis in these areas
• Neurons and axons are not as severely affected, but significant loss may occur
• Globoid cells
Hallmark of the disease, hence the alternate term globoid cell leukodystrophy
Multinucleated giant phagocytic cells up to 50 m in diameter; up to 20 nuclei
PAS-positive due to cerebroside accumulation
Concentrated around blood vessels
On EM, contain cytoplasmic inclusions with straight or tubular profiles
appearing crystalloid in cross section
Decrease in number as disease progresses

Fig. 21. Krabbe disease. (A) Coronal section of the brain stained with oil red O. Only a few myelinated areas stain. The
remainder of the white matter does not stain, indicating loss of myelin. (B) Microscopic section of brain with globoid cells in
white matter. The brain does not store the substrate, galactosylceramide, but it stimulates infiltration of macrophages which
transform to globoid cells. The increased levels of psychosine that occur have cytotoxic effects.

spaces contain an accumulation of rounded mononuclear or binucleated PAS-positive globoid cells 15
to 20 m in diameter (Fig. 21B). The cells are Sudan black-positive and glial fibrillary acidic protein
(GFAP)-negative and stain strongly for Ricinus communis agglutinin and less strongly for peanut and
wheat germ agglutinin. By EM, tubular structures (Fig. 22A) are seen similar to those observed in
Gaucher disease except for the counterclockwise spiral of the tubules (Fig. 22B).
Consistent with the myelin loss, the white matter is evenly depleted of all lipids, particularly glycolipids. The ratio of galactocerebroside to sulfatide is abnormally high. Segmental demyelination, axonal
degeneration, fibrosis, and macrophage infiltration are common in the peripheral nervous system [111].
2.5. Farber disease (lipogranulomatosis)
Lipogranulomatosis was initially described at a Mayo Foundation lecture in 1947 by Sidney Farber,
a pediatric pathologist working at Boston Children’s Hospital. He first published a short description
of the disease in 1952 as a transaction from the 62nd Annual Meeting of the American Pediatric
Society [122], and later published an expanded description in 1957 [123]. Dr. Farber proposed that
the disease had characteristics intermediate between Niemann-Pick disease (lipid storage) and HandSchüller-Christian disease, a histiocytosis (inflammatory infiltrates). The stored lipid was subsequently
identified as ceramide in 1969 [124], and the deficient enzyme was noted to be ceramidase in 1972
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Fig. 22. Krabbe disease. Electron micrograph of brain. (A) A globoid cell containing tubules with electron-dense deposits.
(B) High magnification of the twisted tubule with a counterclockwise spiral.

Fig. 23. Farber disease. (A) Child with multiple skin nodules. (B) Large nodules on the wrist and (C) on the ankle. (Courtesy
of Dr. Steven Qualman.).

[125]. Farber disease manifests clinically with the diagnostic triad of hoarseness, painful and swollen
joints, and periarticular and subcutaneous nodules (Fig. 23) particularly over pressure points [126].
Cherry-red spots have been occasionally described [127–129]. In most cases, there is no significant
visceral involvement. Farber disease often leads to death within the first few years of life due to
respiratory infections. The presentation may be in infancy, with hoarseness, respiratory difficulty,
vomiting, swollen painful joints, and failure to thrive. There is significant clinical variability among
sibs with Farber disease [130], and some patients follow a more prolonged course. These milder cases
can be misdiagnosed as juvenile idiopathic arthritis [131].
Definitive diagnosis is made by determining lysosomal acid ceramidase activity in leukocytes or
cultured skin fibroblasts. Acid ceramidase activity in heterozygotes is usually reduced [126]. Biopsy
of periarticular tissues may be diagnostic. Prenatal diagnosis has been accomplished by demonstrating
acid ceramidase deficiency in cultured amniotic fluid cells. Farber disease patients have a significant
elevation of ceramide in tissue or body fluids [126], but ceramide is difficult to detect histologically
because of its lack of specific staining reactions [132]. The nonspecific oil-red-O positivity and periodic
acid-Schiff-diastase (PAS-D) positivity may reflect peripheral deposition of ceramide and a ganglioside, respectively. Tissue analysis for stored ceramide may prove especially useful, since the ceramide
may be demonstrated in formalin-fixed tissues and has a specific 2-hydroxy fatty acid component. The
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Figs. 24, 25. Farber disease. The opened abdominal cavity at autopsy shows a greatly enlarged liver that has a yellow
appearance. (Courtesy of Dr. Steven Qualman.); (25) Farber disease. Microscopic section of the liver. The hepatocytes are
distended with lipid. (Courtesy of Dr. Steven Qualman.).

gene for Farber disease, ASAH1, has been identified. Biallelic mutations in the same gene also cause
spinal muscular atrophy with progressive myoclonic epilepsy [133]. There is no specific treatment for
Farber disease at present, although a recombinant human acid ceramidase has been produced and is
currently in preclinical studies [134].
Pathologically, foam cells with granulomatous reaction occur in the respiratory system, soft tissues, and joints [135]. The cells are vacuolated and foam cells are present in lymph nodes, bone
marrow, spleen, and liver as well as renal proximal tubular epithelial and glomerular cells. Ceramide,
mucopolysaccharides, and gangliosides accumulate. By EM, foam cells containing curvilinear tubular
structures, membrane-bound reticulogranular material, mucopolysaccharides, and zebra bodies are
seen [136]. The characteristic ultrastructural finding is the so-called “Farber body”, a comma-shaped
curvilinear, tubular intracytoplasmic inclusion [136] thought to reflect ceramide storage. This inclusion is not present in liver cells but is present in macrophages and Kupffer cells. “Banana bodies” are
needle-like, membrane-bound structures found in Schwann cells [137], while zebra bodies are seen in
endothelial cells, neurons and secretory cells from sweat glands [138].
In some cases, gross and microscopic autopsy findings can show massive organomegaly. The liver is
enlarged and pale and has a yellow appearance (Fig. 24). The hepatocytes are distended with lipid, and
histiocytic cells massively infiltrate hepatic sinusoids (Fig. 25) and splenic red pulp with replacement
of the white pulp. The lymph nodes are diffusely enlarged by histiocytic infiltrates that stain with PAS
(Fig. 26). The histiocytes replace lymphoid parenchyma in the medullary and cortical areas, sparing
subcapsular and trabecular sinuses. Patchy histiocytic infiltrates are noted in the bone marrow; the
marrow is cellular with all normal hematopoietic elements in adequate numbers. Erythrophagocytosis
in lymph nodes, bone marrow, liver, and spleen may be seen. Ultrastructurally, typical curvilinear
“Farber” bodies are present (Fig. 27).
There are nodules (Fig. 28) and significant infiltration of the vocal cords causing marked narrowing of
the larynx (Fig. 29) and of the soft tissues and skeletal muscles of the larynx by histiocytes (Fig. 30) with
large pools of extracellular storage material causing swelling and obstruction of the laryngeal lumen.
Storage material is present in subcutaneous nodules at the wrists, knees, and ankles with a peripheral
histiocytic infiltrate and central necrosis [130] and in the joint synovium and lungs (Fig. 31). The heart
may show epicardial nodules (Fig. 32) due to histocytic granulomas (Fig. 33), and the lungs may be
infiltrated with histiocytic cells (Fig. 34).
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Figs. 26–28. Farber disease. Microscopic section of a lymph node showing PAS-positive storage histiocytes. (Courtesy of
Dr. Steven Qualman.); (27) Farber disease. Electron micrograph of Farber’s lipogranulomatosis. Typical curvilinear bodies
(arrowheads) are shown. (Courtesy of Dr. James Phillips.); (28) Farber disease. Dense white nodules removed from the
larynx. (Courtesy of Dr. Steven Qualman.).

Figs. 29–31. Farber disease. Section of larynx greatly narrowed by infiltration of storage histiocytes (right) compared with
normal larynx (left). (Courtesy of Dr. Steven Qualman.); (30) Farber disease. Microscopic section of larynx showing large
distended vacuolated histiocytes. (Courtesy of Dr. Steven Qualman.); (31) Farber disease. Microscopic section of the joint
synovium with infiltration by storage histiocytes.

Figs. 32–34. Farber disease. The heart shows epicardial nodules. (Courtesy of Dr. Steven Qualman.); (33) Farber disease.
Microscopic section of heart showing epicardial infiltration by storage histiocytes. PAS stain. (Courtesy of Dr. Steven
Qualman.); (34) Farber disease. Microscopic section of the lung showing infiltration by storage histiocytes.

Histiocytic cells in the liver store flocculent, granular material in membrane-bound intracytoplasmic
vacuoles. Storage vacuoles are occasionally present within hepatocytes.
Renal storage disease has been documented morphologically and biochemically with elevated
ceramide levels in the renal parenchyma or urine in severely affected patients [136, 139] as well as in the
fetus. Kidneys show storage material within both glomerular podocytes and proximal tubular epithelial
cells with membrane-bound accumulations of flocculent granular material but no curvilinear tubular
inclusions. There may be moderate nervous system dysfunction related to the accumulation of ceramide
and gangliosides in neurons (Fig. 35) [130] and in the anterior horn cells of the spinal cord (Fig. 36).
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Figs. 35, 36. Farber disease. Microscopic section of the cerebral cortex of the brain. The neurons are distended with storage
material; (36) Farber disease. Microscopic section of spinal cord. The anterior horn cells are distended with storage material.
(Courtesy of Dr. Steven Qualman.).

Liver, spleen, and subcutaneous nodules contain a highly water-soluble, PAS-D-resistant cytoplasmic
substance within histiocytes. Oil red O-positive lipid, present within histiocytes in formalin-fixed
tissue, is lost during paraffin embedding. Distinct PAS-D-positive and oil red O-positive substances
are detected in both thickened glomerular capillary loops and vacuolated proximal tubular epithelial
cells in the kidneys.
Although subcutaneous nodules of Farber disease have a distinct histopathologic appearance on
biopsy, they are not universally diagnostic of Farber disease and may be absent [126]. Lymph nodes
may be the most accessible tissue for biopsy and diagnosis, if palpable subcutaneous nodules are absent.
Lymph node involvement has been seen more frequently in Farber disease than in other visceral sites
of storage. The sparing of lymph node sinuses by the disease is in contradistinction to the histiocytic
proliferative disorders, which often involve lymph nodes but primarily involve the sinuses [140].
2.6. Fabry disease
The disease was described independently in 1898 by two dermatologists, Johannes Fabry in Germany
and William Anderson in England [141, 142]. Fabry disease is an X-linked inborn error of glycosphingolipid catabolism resulting from the deficient activity of the lysosomal hydrolase ␣-galactosidase A in
tissues and fluids [143, 144]. The enzyme defect leads to the systemic deposition of glycosphingolipids
with terminal ␣-galactosyl moieties, predominantly globotriaosylceramide and, to a lesser extent,
galactosylceramide and blood group B antigens. Hemizygous males have extensive deposition of
these glycosphingolipid substrates in body fluids and in the lysosomes of endothelial, perithelial, and
smooth muscle cells of blood vessels. Deposition also occurs in ganglion cells, and in many cell types
in the heart, kidneys, eyes, and most other tissues [145].
Fabry disease results from mutations in the gene encoding ␣-galactosidase A, i.e., GLA. This gene,
which has been localized to chromosome Xq22, has 7 exons and encodes a 429 amino acid protein
with a 31-amino acid signal peptide. More than 750 different mutations in GLA have been identified
[143]. Prevalence estimates range from 1 in 50,000 to 1 in 117,000 [143]. A high prevalence of the
cardiac variant was found in Taiwan, where it is estimated to affect 1 in 1,600 males [146].
Clinical manifestations in classically affected hemizygotes who have no detectable ␣-galactosidase
A activity include the onset of pain and paresthesias in the distal extremities (acroparesthesias), vessel
ectasia (angiokeratoma) in skin and mucous membranes, hypohidrosis during childhood or adolescence, corneal and lenticular opacities, and tortuous conjunctival vessels (Fig. 37). With increasing
age, proteinuria, hyposthenuria, and lymphedema appear. Severe renal impairment leads to hyperten-
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Fig. 37. Fabry Disease. (A) Corneal whorls, representing storage of trihexosylceramide. (B) Angiokeratomata of umbilicus.
(C) Tortuous vessels in bulbar conjunctiva.

sion and uremia. Death usually occurs from renal failure or from cardiac or cerebrovascular disease.
Atypical hemizygotes with residual ␣-galactosidase A activity may be asymptomatic or have late-onset,
mild disease manifestations primarily limited to the heart (the “cardiac variant”) [143].
Heterozygous females may have an attenuated form of Fabry disease. They are usually asymptomatic,
although rarely can be as severely affected as hemizygous males. The most frequent clinical finding in
females is the characteristic whorl-like corneal epithelial dystrophy observed on slit-lamp examination
[143].
Confirmation of the clinical diagnosis in hemizygotes and heterozygotes requires the demonstration
of deficient ␣-galactosidase A activity in plasma, leukocytes, or tears, or increased levels of globotriaosylceramide in urine. Heterozygous females may have intermediate levels of enzyme activity and
accumulated substrate. The more accurate diagnosis of heterozygous females can be accomplished
by detection of the molecular lesion in GLA. Prenatal diagnosis can be accomplished by demonstration of deficient ␣-galactosidase A activity and XY karyotype, or by demonstration of the specific
␣-galactosidase A mutation in chorionic villi or cultured amniotic cells [143, 144].
Enzyme replacement therapy is now the treatment of choice for Fabry disease. In addition, supportive
measures include low maintenance dosages of diphenylhydantoin, gabapentin or carbamazepine to
relieve the excruciating pain and constant discomfort of acroparesthesias. Oral anticoagulants are
recommended for stroke-prone patients. Renal dialysis and transplantation are effective in the treatment
of end-stage renal disease.
With respect to the pathology of Fabry disease, glycosphingolipids (principally the trihexosyl
ceramide globotriaosylceramide) accumulate in all organs and tissues [147] and may be up to 300-fold
higher than normal levels [148]. Immunohistochemistry using antibodies against globotriaosylceramide is possible [149]. The greatest accumulation is observed in kidney, lymph nodes, blood
vesels, prostate, and autonomic ganglia (Fig. 38A) [147]. The storage has a predilection for vascular endothelium (Fig. 38B) and smooth muscle cells, which is different from that seen in other
forms of glycosphingolipidoses [147]. The major abnormalities of vessels are narrowness, dilation,
and motor unresponsiveness. In addition to endothelial proliferation, the swollen endothelial cells may
be the precursor of thromboses, ischemia, and infarction, and there may be progressive aneurysmal
dilation of the weakened vessel walls. Microaneurysms may form in retinal and conjunctival vessels,
and in the skin a transition from telangiectasia to a frank angiokeratoma is one of the hallmarks of the
disease [147]. The involvement of peripheral and central autonomic nerve cells may be responsible for
paresthesias, pain, gastrointestinal symptoms such as nausea and diarrhea, and other vague neurologic
symptoms. In the eye, lipid deposits can be seen in the basal cells of the corneal epithelium and in
the epithelial cells of the lens [150]. Lipid storage has also been found in Leydig cells of the testis
and basal cells of the epididymal ducts [151, 152]. Pathologic changes occur in the kidney (Fig. 39)
with accumulation of glycosphingolipid in the glomerular visceral, glomerular parietal, and tubular
epithelial cells. Subendothelial deposits of membrane-like material associated with duplications of the
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Fig. 38. Fabry disease. (A) Microscopic section of the myenteric plexus showing large distended ganglion cells that are PASpositive. (B) Microscopic section of a blood vessel showing thickening of the vessel wall by accumulation of glycosphingolipid
(PAS stain).

Fig. 39. Fabry disease: kidney. (A) Gross appearance of end-stage disease with scarring and cyst formation. External view
(left), cut surface (right). (B) Microscopic section of kidney glomerulus. Foamy glomerular epithelial cells are present. (C)
Electron micrograph of kidney. Glomerular epithelial cells contain myelin-like figures. (D) Glomerular parietal epithelial
cells show pleomorphic lipid inclusions.

glomerular basement membrane have also been described [153]. Vacuolated epithelial cells known as
oval fat bodies can be seen in the urine sediment [154]. A scoring system for the renal pathology has
been developed [155].
In histologic sections, the deposits of ceramide trihexoside appear as vacuoles, and in frozen sections
they are sudanophilic, PAS-positive, and strongly birefringent under polarized microscopy. In cardiac

32

A

C.R. Ferreira and W.A. Gahl / Lysosomal storage diseases

B

Fig. 40. Fabry disease. (A) Large distended ganglion cells in gasserian ganglion. Hematoxylin and eosin stain (left); Luxol
fast blue stain (right). (B) Electron micrograph shows concentric parallel lamellae of the lipid storage substance.

muscle, the deposits occupy the central perinuclear areas of the cytoplasm displacing the contractile
elements to the periphery. This results in the histologic appearance of a lacework pattern similar to that
seen in type II glycogenosis. Ganglia are distended with storage material (Fig. 40). Ultrastructurally,
the storage material is deposited in lysosomes with concentric or parallel lamellae with a periodicity of
4 to 55 nm. These concentric lamellar bodies are known as myelin figures. The lamellae react positively
with periodate-thiosemicarbazide silver proteinate and periodate-thiosemicarbazide-osmium tetroxide.
These structures can also be demonstrated on freeze-fractured preparations [147].
The histopathologic changes frequently involve the heart, especially the myocardial cells, specialized
tissues of the atrial ventricular conduction system, and the valves [148, 156] and the coronary arteries,
due to deposition of glycosphingolipid. Hypertrophic obstructive cardiomyopathy has been noted
[157]. The aorta may show changes suggestive of cystic medionecrosis [147]. In a patient on longterm enzyme replacement therapy, the typical myelin-like figures were lost, being replaced instead by
crystalline tubular structures and abnormally-branched glycogen [158].
The severity of this disorder appears to be related to the total amount of the glycosphingolipid stored
in the tissues, which in turn depends on time, the presence or absence of residual ␣-galactosidase A
activity, and the individual’s ABO blood type. Hemizygotes and heterozygotes who are type B and AB
are more severely affected because of the additional accumulation of B-specific glycosphingolipid,
with a terminal ␣-galactosyl residue (Fig. 41).
The cutaneous lesion (angiokeratoma) is not distinctive for Fabry disease. Angiokeratomas also occur
in fucosidosis, adult-onset GM1 gangliosidosis (␤-galactosidase deficiency), aspartylglucosaminuria,
␣-N-acetylgalactosaminidase deficiency (Schindler neuroaxonal dystrophy syndrome and Kanzaki
disease), sialidosis type II, galactosialidosis (Goldberg syndrome), and ␤-mannosidosis.
2.7. Schindler disease
The disease was first described by Detlev Schindler and colleagues in 1987, who reported two German
brothers with profound intellectual disability, seizures, blindness and decorticate posturing caused by
␣-N-acetylgalactosaminidase (␣-NAGAL) deficiency [159]. Thin-layer chromatography of urinary
oligosaccharides revealed an abnormal pattern, and the older sibling, whose blood group was type A,
was noted to excrete 5 times the normal level of the group A determinant, a trisaccharide with a terminal
␣-N-acetylgalactosamine. Subsequently, the degradation rate of blood group A glycosphingolipids has
been found to be low in fibroblasts from patients with ␣-NAGAL deficiency [160], supporting the notion
that patients with blood group A have worse storage disease (Fig. 37). ␣-NAGAL is also known as
␣-galactosidase B, and the NAGA gene encoding for this enzyme shares 46% sequence identity with
the GLA gene, encoding for ␣-galactosidase A (the enzyme deficienct in Fabry disease). In fact, both
genes derive from a common ancestor [161].
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Fig. 41. The terminal residue of blood group antigen B is metabolized by ␣-galactosidase A–deficient in patients with Fabry
disease–while antigen A is cleaved by ␣-galactosidase B–deficient in patients with Schindler’s disease.

This rare, autosomal recessive lysosomal storage disease has three main phenotypes: Schindler
disease type I, an infantile-onset neuroaxonal dystrophy; type II, an adult-onset disorder with mild
intellectual disability, and type III with an intermediate phenotype accompanied by mild to moderate
neurologic involvement [162].
Schindler disease type I is characterized by onset around the second year of life with weakness,
hypotonia, and areflexia. As the disease progresses, rigidity, spasticity, cerebellar signs, deafness,
blindness, and mental deterioration occur. Death occurs typically before the age of 6 years. Clinically
and histopathologically, the disease mimics Seitelberger disease, with characteristic spheroids seen in
terminal axons.
Type II disease was first reported in 1989 by Kanzaki and colleagues, who described a 46-year-old
Japanese woman with angiokeratoma corporis diffusum and glycoprotein storage [163]. Since the
glycopeptiduria found in this patient was similar to that found in the original German siblings with
Schindler disease, Kanzaki and colleagues measured the activity of ␣-NAGAL and found it to be
deficient [164]. Thus, ␣-NAGAL deficiency type II is also known as Kanzaki disease. Although the
original Japanase proband was initially reported as not having neurologic involvement, more careful
phenotyping revealed mild intellectual disability and peripheral neuropathy [165]. The same patient was
reported once more in 2004, by which time she had developed sensorineural hearing loss and recurrent
vertigo attacks [166]. Other cases of Kanzaki disease have been associated with Ménière’s disease,
hearing loss and peripheral neuropathy [167]. Variable features include tortuosity of conjunctival
and retinal vessels [165, 168], cardiac involvement in the form of moderate cardiomegaly [168] or
hypertrophy of the interventricular septum [167], and lymphedema [168]. Pathologic findings include
markedly dilated lysosomes producing vacuolation of endothelial cells, fibroblasts, Schwann cells, and
secretory cells of eccrine sweat gland [163, 165, 167, 168]. Small cytoplasmic vacuoles have been found
in lymphocytes, granulocytes and monocytes on peripheral blood smears stained with Giemsa [165].
The first case of ␣-NAGAL deficiency type III was described in 1993 in a girl with generalized
seizures starting at 11 months of age, and mild but persistent oligosacchariduria [169]. No vacuolization
was seen in lymphocytes, granulocytes or monocytes. Interestingly, her younger brother had a similar
degree of ␣-NAGAL deficiency but remained asymptomatic by the age of 8 year [170]. A similar
case of an asymptomatic patient with ␣-NAGAL deficiency ascertained through an affected sibling
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with type III disease was subsequently described [170]. Interestingly, these two siblings carried the
same homozygous E325K mutation in NAGA as the original German siblings with type I disease,
arguing against a genotype-phenotype correlation. In fact, the ␣-NAGAL activity in fibroblasts from
two patients with milder Kanzaki disease was found to be lower than in patients with Schindler disease
types I and III [171].
There is no treatment for the disease, although two pharmacological chaperones – 2-acetamido-1,2dideoxy-D-galactonojirimycin (DGJNAc) and 1-deoxygalactonojirimycin (DGJ) – have been proposed
as potential therapeutic agents [172].
2.8. GM1 Gangliosidosis type I (Norman-Landing disease)
The gangliosidoses are autosomal recessive conditions and are divided into 2 major groups, GM1 and
GM2 gangliosidoses [173]. Until the mid-1960s, GM2 gangliosidosis remained the only ganglioside
storage disease known. In 1959, Norman and colleagues described a patient with cherry-red spots,
hepatomegaly caused by infiltration of foamy histiocytes, and facial features similar to those seen in
Hurler disease [174]. Landing and colleagues reviewed eight similar cases in 1964 [175]. O’Brien and
colleagues identified the stored material as a ganglioside, structurally different from the compound
that accumulates in Tay-Sachs disease [176]. A deficiency of ␤-galactosidase was identified as the
underlying etiology in 1968 [177]. The same enzymatic deficiency can lead to Morquio disease type
B [178]. When glycosaminoglycans fail to have their terminal galactose removed, as in bone and
connective tissue, the result is Morquio type B disease. When ganglosides fail to have their terminal
galactose removed, as in neurons, the result is GM1 gangliosidosis.
GM1 gangliosidosis is a neurosomatic disease occurring mainly in early infancy (infantile form, type
I). Developmental arrest is observed a few months after birth, followed by progressive neurologic deterioration and generalized spasticity with sensorimotor and psychointellectual dysfunctions. Macular
cherry-red spots occur in 50% of patients; facial dysmorphism, hepatosplenomegaly, and generalized
skeletal dysplasia are usually present in infantile cases. Extrapyramidal signs and dystonia are the
major neurologic manifestations in adults with GM1 gangliosidosis [173].
The human ␤-galactosidase gene, GLB1, has been mapped to chromosome 3 and has 16 exons
encoding a 76 kDa protein. More than 180 mutations have been described [31], including the common
mutations, R201C, I51T, and W273L, found in Japanese or Caucasian patients with late infantilejuvenile GM1 , with adult-chronic GM1 gangliosidosis, and with Morquio B syndrome, respectively.
The Romani population also harbors a founder mutation, p.R59H [179, 180]. The estimated prevalence
varies from 1 in 100,000 to 1 in 300,000 [178], with a much higher prevalence in southern Brazil [181],
the Maltese islands [182], and the Romani population [183].
Glycoconjugates with terminal ␤-galactose are increased in tissues and urine from patients with
GM1 gangliosidosis and Morquio B syndrome. The ganglioside GM1 and its asialo derivative GA1
accumulate in the brain of GM1 -gangliosidosis patients. Oligosaccharides derived from keratan sulfate
or glycoproteins have been reported in visceral organs and urine from patients with GM1 gangliosidosis.
Deficient activity of ␤-galactosidase results in accumulation of ganglioside in neurons, and in other
sites the defect causes accumulation of mucopolysaccharides (glycosaminoglycans) [175].
Definitive diagnosis by ␤-galactosidase assay is established using leukocytes, dried blood spots,
fibroblasts, or amniocytes. A variant of sialidosis (galactosialidosis) has both sialidase and ␤galactosidase deficiencies.
The brain pathology involves progressive atrophy with neuronal swelling (Fig. 42) and loss of neurons
and gliosis. Neurons contain sudanophilic material (ganglioside) and some PAS-positive material,
whereas other viscera, particularly the liver (Fig. 43) and kidney (Fig. 44), accumulate strongly PASpositive material because of the presence of mucopolysaccharides. By EM [184], MCBs (Fig. 45) as
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Figs. 42, 43. GM1 gangliosidosis type I: brain. The cortical neurons are distended with ganglioside; (43) GM1 gangliosidosis
type I: liver. Some hepatocytes are swollen and contain storage material.

Figs. 44, 45. GM1 gangliosidosis type I: kidney. The glomerular epithelial cells are vacuolated; (45) GM1 gangliosidosis
type I. Electron micrograph in conjunctival biopsy showing typical membranous concentric bodies (MCBs) of gangliosides.
MCBs are the morphologic expression of gangliosides seen in all the gangliosidoses including Tay-Sachs disease.

well as pleomorphic membranous vesicular bodies or large compact oval bodies are seen in skin or
conjunctival biopsy and reticulogranular material is seen in cultured skin fibroblasts and/or endothelial
cells of skin biopsies. Peripheral blood and bone marrow lymphocytes and syncytiotrophoblasts of the
placenta are vacuolated. Other pathologic findings are similar to those in GM1 type II (see below).
In the fetus at midgestation, nervous system involvement is expressed prominently in the most mature
neurons, i.e., in myenteric plexus, spinal cord, cerebellum, and deeper cerebral cortical regions. The
lysosomes are mostly empty, with a few fibrils in neurons of the brain, whereas more mature peripheral
neurons contain membranous inclusions [185, 186]. Lysosomal inclusions have been described in
liver, renal tubules, glomeruli, lymphocytes, and syncytiotrophoblasts of a 17-week-gestation fetus.
The lysosomal pathology is most readily detected by EM in these fetal cases. Little may be evident by
LM, except in the placenta where the trophoblastic epithelium is vacuolated.
2.9. GM1 gangliosidosis type II (Derry’s syndrome)
The late-infantile, or juvenile form of the disease was first described by Derry and colleagues in
1968 [187]. GM1 type II gangliosidosis (juvenile) usually becomes apparent at about 1 year of age
and is clinically and pathologically similar to type I gangliosidosis [186]. The facial features are
characteristic, with prominent philtrum (Fig. 46), hypertrophic gingivae (Fig. 47), enlarged tongue,
and prominent papillae. There are radiologic features of dysostosis multiplex (Fig. 48). Mental and
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Figs. 46, 47. GM1 gangliosidosis type II. Facial appearance at autopsy. Mild anomalies of the ear and a prominent philtrum
are present; (47) GM1 gangliosidosis type II. Appearance of oral cavity at autopsy. Note marked gingival hypertrophy.

Figs. 48, 49. GM1 gangliosidosis type II. Postmortem X-ray. (A) Changes of dysostosis multiplex in skull. (B) Lateral
projection of vertebrae that shows mild generalized platyspondyly of cervical vertebrae and tear-drop deformity of vertebrae; (49) GM1 gangliosidosis type II. Gross appearance of heart opened through the left ventricle. The mitral valve leaflets
are markedly deformed and thickended.

motor deterioration begins after the first year of life. Viscera are usually not significantly enlarged
and only subtle bone changes may be present. Deficiency of ␤-galactosidase results in excessive
accumulation of GM1 ganglioside and its asialo derivative in the CNS and of a keratan sulfate-like
galactose-containing proteoglycan in viscera.
The most consistent pathologic changes of GM1 gangliosidosis (Table 14) include: (i) neuronal
lipidosis, swelling of neurons, presence of abnormal neuronal cytoplasmic organelles; (ii) swelling
of the renal visceral glomerular epithelium and other renal parenchymal cells; (iii) severe cardiac
valvular involvement with excessive deposition of mucopolysaccharide in heart valves; and (iv) the
presence of foamy histiocytes in the liver, spleen, lymph nodes, and bone marrow. The cytoplasmic
inclusions in visceral histiocytes are PAS-positive, Alcian blue-positive, weakly metachromatic, and
weakly sudanophilic. The neuronal lipidosis occurs throughout the cortex, brainstem, and spinal cord
and also in the myenteric plexus. The neuronal cytoplasm is ballooned with storage material displacing
the nucleus to the periphery. The storage substance appears as finely dispersed particles in LM. These
manifestations characterize both forms of the disease, but are more extensive in type I [186].
Unlike the myocardial involvement in GM1 type I the myocardial cells of GM1 type II do not appear
to contain storage material [186]. Both mitral and aortic valve leaflets are thickened (Fig. 49), retracted,
and markedly deformed, and fused with the chordae tendineae. The valve cusps contain vacuolated
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Table 14
Pathologic manifestations of 3 siblings with GM1 gangliosidosis type II

General Features
Contractures
Hypertrophy of gums
Lumbar kyphosis
Exotropia
Mildly thickened tongue
Heart
Cardiomegaly
Valves thick, rigid, and retracted
Storage histocytes in valve leaflets (Alcian blue, PAS, and toluidine blue positive)
Spleen
Splenomegaly
Storage histiocytes
Liver
Hepatomegaly
Alcian blue, PAS, and toluidine blue positive material in hepatocytes
Alcian blue, PAS, and toluidine blue positive material in Kupffer cells
Lipid in hepatocytes
Brain
Weight below normal
Leptomeninges thick and fibrotic
Marked to severe atrophy of cerebral and cerebellar cortices
Loss of cerebral cortical neurons, extensive
Loss of neurons, brain stem nuclei
Storage material in neurons of cerebral cortex, cerebellar cortex, and brainstem nuclei
Spinal cord
Storage material in anterior horn cells
Kidneys
Vacuolation of glomerular visceral epithelium
Vacuolation of tubular epithelium
Intestine
Storage material in myenteric plexus
X-Ray Findings in Bones
Cortical thinning of long bones
Anterior protrusion, lower sternum
Hypoplasia, vertebral bodies
Osteosclerosis, calvarium and base of anterior fossa

Case 1

Case 2

Case 3

+
+
+
+

+
+
+
+

+
+
+
+
+

+
+
+

–
+
+

+
+
+

+
+

+
+

+
+

+
–
–
+

+
+
+
+

+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+

+
+
+
+
+
+

+

+

+

+
+

+
+

+
+

+

+

+

+

+
+
+
+

histiocytes (Fig. 50). The aorta and its major branches show no evidence of intimal thickening or
plaques [186]. Electron micrographs of cytoplasm of storage histiocytes from the heart valves show
(i) membrane-bound structures filled with reticulo-granular material and (ii) membranous arrays with
circular profiles.
The brain has marked, diffuse atrophy of the cerebral cortex (Fig. 51) and of the cerebellar cortex
including the vermis. The consistency of both cerebral and cerebellar tissues is firmer than usual. On
section, hydrocephalus ex vacuo may be present. The corpus callosum is extremely thin, measuring
only 1 mm in its posterior portion [186]. Most of the nerve cells are distended with granular cytoplas-
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Figs. 50–52. GM1 gangliosidosis type II. Microscopic section of mitral valve showing vacuolated histiocytes and intense
staining of collagen. Alcian blue stain; (51) GM1 gangliosidosis type II. Gross appearance of brain showing atrophy of
cerebral hemisphere, particularly the frontal and occipital lobes; (52) GM1 gangliosidosis type II. Microscopic section of
cerebellar cortex showing large distended Purkinje cells. PAS stain.

Figs. 53–55. GM1 gangliosidosis type II. Microscopic section of spinal cord showing large vacuolated anterior motor neurons.
PAS stain; (54) GM1 gangliosidosis type II. Electron micrograph of cerebral cortical neuron. Membranous cytoplasmic
bodies (MCB) in neuronal perikaryon; (55) GM1 gangliosidosis type II. Electron micrograph of cerebral cortical neuron. The
cytoplasm is filled with pleomorphic lipid bodies (PLB).

mic inclusions. Similar changes are seen in the cerebellum, where Purkinje cells and their dendritic
processes are swollen to varying degrees and contain cytoplasmic granules with the same staining characteristics (Fig. 52). Astrogliosis and microglial mobilization with glitter cell formation are present in
all affected parts of the brain [186]. The anterior horn cells of the spinal cord are large, distended, and
vacuolated (Fig. 53). Sections from cerebral and cerebellar cortices show inclusions in the perikarya
of neurons and glial cells, and also in the processes of Purkinje cells. Three types of inclusions are
identified. MCBs (Fig. 54) are present in most neuronal perikarya and their processes and in glial cells.
Their size varies, the largest being 3 m in diameter. They consist of alternating electron-lucent and
electron-opaque bands with a periodicity of 60 Å with no limiting membrane [186].
Pleomorphic lipid bodies (PLBs) are also observed in nerve and glial cells (Fig. 55), as are stacked or
circularly arranged lamellae (Fig. 56). Occasionally the lamellae are tightly packed with a periodicity
of 30 Å. More often, however, the periodicity is 60 Å, as in the MCBs. In some areas the granular
material appears to represent fragments of the lamellae. The PLBs are often surrounded by a limiting
membrane [186].
The involvement by PAS-positive deposits in renal glomerular epithelial cells is a characteristic
of GM1 gangliosidosis [175] not seen in other types of lipid storage diseases except Fabry disease
[188], I-cell disease [189] and Farber disease. The glomerular epithelial cells store large quantities of
cytoplasmic PAS-positive material that is excreted in the urine in both the infantile and juvenile types of
GM1 gangliosidosis [190]. Hence toluidine blue and Alcian blue tests for urine mucopolysaccharides
may be positive.
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Figs. 56, 57. GM1 gangliosidosis type II. Electron micrograph of glial cell containing cytoplasmic inclusion displaying
unusual lamellar pattern; (57) GM1 gangliosidosis type II. Electron micrographs of tubular inclusions (T) in cytoplasm of
splenic macrophage. Mosaic-like pattern of membrane bounded compartments filled with tubules.

The visceral histiocytes in GM1 gangliosidosis appear to be enlarged chiefly due to storage of
mucopolysaccharides rather than of gangliosides. The Kupffer cells, some hepatocytes, and splenic
histiocytes show lipid inclusions with electron-dense or, less frequently, with electron-lucent centers
and deposits of tubular structures (Figs. 57 and 58). Suzuki et al. [191] demonstrated that in juvenile GM1 gangliosidosis the liver and spleen contain approximately 10 times the normal amount of
mucopolysaccharide, which is similar to keratan sulfate. The concentration of this keratan sulfate-like
mucopolysaccharide in the liver is greater in generalized gangliosidosis than in the juvenile form [186].
Lysosomal membrano-granular material, reflecting mucopolysaccharide, accumulates in the visceral
histiocytes of GM1 gangliosidosis. The tubules contained within the cytoplasm of Kupffer cells and of
splenic macrophages are strikingly similar to those described by Suzuki et al. [192] in macrophages
of the liver and spleen and by Lowden et al. [193] in macrophages of liver, spleen, and bone marrow
of the same disease. The former investigators give the width of the tubules as approximately 200 Å.
Membrane-bound cytoplasmic deposits of tubules have also been reported for Krabbe disease [194] and
Gaucher disease [195]. However, the tubules seen in the globoid cells of the brain appeared distinctly
twisted in transmission electron micrographs and ranged from 225 to 350 Å in width. Tubules found
in Gaucher cells of the liver and spleen also appeared twisted and measured 400 to 600 Å in width.
Chemical analysis of the tubules of any of the aforementioned conditions has not been performed.
Lee [196] compared by transmission electron microscopy the tubule of purified cerebroside with the
tubules in a fractionated preparation of Gaucher cells and concluded that the latter contained a protein
component, seen as fine fibrils, that was not present in the cerebroside. The histiocytes of the bone
marrow have a “crinkled paper” appearance resembling that of the Gaucher cell [193]. The bone
marrow contains large histiocytes (Fig. 59), and the liver (Fig. 60), kidney (Fig. 61), and myenteric
plexus (Fig. 62) show storage cells.
No morphologic differences have been demonstrated between the MCBs seen in GM1 gangliosidosis
and those of Tay-Sachs disease; acid phosphatase activity has also been demonstrated in MCBs of
Tay-Sachs disease [197].
Ultrastructural studies of the retina in both types of GM1 gangliosidosis demonstrated MCBs in
ganglion cells [198]. MCBs have also been observed in the processes of Miller cells [199]. Clinical
and LM evidence of retinal involvement has not been documented in the juvenile form of this disease.
Neurons of fetal brain in GM1 and GM2 gangliosidosis have been found to contain MCBs [200].
However, in fetal brain, they were described as incompletely developed and as lacking the compactness
of mature MCBs [186].
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Figs. 58–60. GM1 gangliosidosis type II. Electron micrograph of tubular inclusions in cytoplasm of splenic macrophage with
curved tubules at higher magnification and cut obliquely; (59) GM1 gangliosidosis type II. Microscopic section of marrow
with large histiocytes containing PAS positive material. PAS stain; (60) GM1 gangliosidosis type II. Microscopic section of
liver showing Kupffer cells distended with storage material.

Figs. 61, 62. GM1 gangliosidosis type II. Microscopic section of kidney showing enlarged visceral glomerular epithelial cells
containing granules; (62) GM1 gangliosidosis type II. Microscopic section of gastrointestinal tract showing ganglion cells in
the myenteric plexus. One ganglion cell contains granular deposits stained deeply with Luxol fast blue.

2.10. GM1 gangliosidosis type III (adult or chronic)
This disorder is a milder version of types I and II, with onset in the teens and lack of visceral
involvement. GM1 gangliosides accumulate in the central nervous system, especially the basal ganglia,
and keratan sulfate degradation products accumulate in somatic cells. More than half of all patients
reported in the literature are from Japan [201]. The most common presentation is that of progressive
generalized dystonia, and almost half of all patients have associated akinetic-rigid parkinsonism [201].
Facial dystonia, seen in approximately 90% of patients, is an important diagnostic clue [202, 203].
Gait and speech disturbances–the latter in the form of dysarthria or anarthria–are almost universal
during the course of the disease [201]. Bilateral putaminal hyperintensities on T2-weighted magnetic
resonance imaging can be seen in about half of all cases, especially in Japanese patients [201]. In rectal
biopsies, histiocytes with PAS-positive granules can be seen in the mucosa, while ultrastructurally the
ganglion cells of Meissner’s plexus have osmiophilic lamellar inclusions [204–206].
2.11. GM2 gangliosidoses
Tay-Sachs disease was first described by a British ophthalmologist, Waren Tay, in 1881 [207]. The
original patient died soon afterwards, but Dr. Tay reported a more complete clinical description of the
disease in a second patient from the same family in 1884. An American neurologist, Bernard Sachs,
first published the brain cortical pathology of the disease in 1887 [208]. Ernst Klenk, in Cologne, first
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detected a new glycosphingolid in brains from patients with Tay-Sachs disease and Niemann-Pick
disease [209], and later coined the term ganglioside since the same lipid was found in abundance in
normal ganglion cells [210]. The deficiency of hexosaminidase enzymatic activity was not discovered
until 1969 [211], although a year earlier Sandhoff, Andreae and Jatzkewitz had described a more
generalized form of hexosaminidase deficiency, with the additional finding of globoside storage in
visceral organs [212].
GM2 gangliosidoses are autosomal recessive disorders caused by deficiency of ␤-hexosaminidase
and, consequently, excessive intralysosomal accumulation of ganglioside GM2 and related glycolipids, particularly in neuronal cells [213]. The enzymatic hydrolysis of ganglioside GM2 by
␤-hexosaminidase requires that GM2 be complexed with a substrate-specific cofactor, the GM2 activator. There are 2 isoenzymes of ␤-hexosaminidase: Hex A, consisting of 2 subunits, ␣ and ␤; and
Hex B, a homodimer of ␤ subunits. Only Hex A can act on the ganglioside GM2 -GM2 activator complex. Defects in any of 3 genes may lead to GM2 gangliosidosis: HEXA (on chromosome 15), which
encodes the ␣ subunit of Hex A; HEXB (on chromosome 5), which encodes the ␤ subunits of Hex A
and Hex B; or GM2A (on chromosome 5), which encodes the GM2 activator. There are 3 forms of
GM2 gangliosidoses: (i) Tay-Sachs disease and variants, resulting from mutations of the HEXA gene
and associated with deficient activity of Hex A but normal Hex B (variant B); (ii) Sandhoff disease
and variants, resulting from mutations of the HEXB gene and associated with deficient activity of both
Hex A and Hex B (variant O); and (iii) GM2 activator deficiency, due to mutation of the GM2A gene
and characterized by normal Hex A and Hex B but the inability to form a functional ganglioside GM2 GM2 activator complex (variant AB). There are also pseudodeficient or clinically benign mutations
characterized by a Hex A enzyme that exhibits biochemical defects but has functional activity toward
ganglioside GM2 . The gross pathologic changes are similar in Tay-Sachs disease, Sandhoff disease,
and GM2 activator deficiency, except that visceral organ involvement is evident in Sandhoff disease.
The most pronounced cellular change is the presence throughout the nervous system of swollen neurons
with massive accumulation of storage material in lysosomes. These form characteristic inclusions, the
so-called membranous cytoplasmic bodies [213].
The hexosaminidases and GM2 activator are glycoproteins that are synthesized in the lumen of the
endoplasmic reticulum and processed through the Golgi. They are transported via the mannose 6phosphate receptor to the lysosome, where they are processed further to their final mature forms.
Hex A and Hex B hydrolyze a broad spectrum of substrates with terminal N-acetylglucosamine
(GlcNAc) residues in ␤ linkage. While only hexosaminidase A hydrolyzes GM2 , both isoenzymes
hydrolyze glycoproteins, glycosaminoglycans, and glycolipids. Both also hydrolyze synthetic substrates, of which the most sensitive and commonly used is a fluorogenic substrate, the ␤-GlcNAc
derivative of 4-methylumbelliferone (4MUG). 4MUG is recognized by both Hex A and Hex B and
does not require the GM2 activator. Hex A and Hex B can be distinguished by different thermal, pH,
or electrophoretic characteristics of the isoenzymes. In particular, hexosaminidase A is heat-labile
at 50◦ C, while hexosaminidase B is heat-stable at that temperature. In addition to 4MUG, a related
compound cleaved by Hex A, but not Hex B, is 4-methylumbelliferyl-GlcNAc-6-sulfate (4MUGS).
Substrates such as 4MUG or 4MUGS are used for routine diagnostic testing and screening for carriers
of HEXA or HEXB mutations [213]. The total serum hexosaminidase activity is measured using 4MUG
as a substrate. A second serum aliquot is exposed to heat, thus inactivating hexaosaminidase A and
reflecting only the activity of hexosaminidase B. The hexosaminidase A activity is then calculated by
substracting the hexosaminidase B activity from the total hexosaminidase activity. One limitation of
this technique is that certain HEXA mutations make hexosaminidase A thermostable, causing the B1
variant of Tay-Sachs disease, in which hexosaminidase A activity is normal when measured by the
standard heat-inactivation technique, but is reduced when using 4MUGS as a substrate. The B1 variant (also known as pseudo-AB, or AMB variant) is more common in patients of Portuguese ancestry
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[214]. The converse can also be true; a mutation in HEXB can render hexosaminidase B thermolabile,
thus mimicking the biochemical phenotype of Sandhoff disease in a normal patient [215], or masking a carrier status for Tay-Sachs disease, since it artificially raises the activity of hexosaminidase
A [216]. Another limitation of the heat-inactivation method is that pregnant women or those taking
oral contraceptives produce a circulating heat-stable hexosaminidase P, which can falsely decrease the
calculated serum activity of hexosaminidase A relative to that of total hexosaminidase. This is why
carrier status in pregnant women or those taking OCPs should be assessed in leukocytes, as opposed to
serum.
Clinical phenotypes in the GM2 gangliosidoses vary widely. Infantile-onset, rapidly progressive
neurodegenerative disease culminates in death before 4 years of age (classic Tay-Sachs disease and
Sandhoff disease, as well as GM2 activator deficiency). Later-onset, subacute, or chronic forms exhibit
slower neurological progression, compatible with survival into childhood or adolescence (subacute
form) or into adulthood (chronic or adult-onset forms) [104]. The most common presenting symptoms
in late-onset cases are balance problems and difficulty climbing stairs [217]. A very characteristic
pattern of predominant triceps, iliopsoas and quadriceps weakness is seen with late-onset disease
[217]. Chronic forms include several different clinical phenotypes, each dominated by symptoms
referable to one or another part of the CNS, including progressive dystonia, spinocerebellar degeneration, motor neuron disease [218–221], spinal muscular atrophy [222–225], and psychosis [213, 226].
Patients with late-onset Sandhoff disease can have autonomic neuropathy [227, 228], which can lead
to acroparesthesias similar to the ones experienced by patients with Fabry disease [229].
There are more than 175 known mutations scattered over the 14 exons of HEXA [31], including
founder mutations among the French Canadians, Cajuns, Irish, and Brazilians [213, 226]. The most
common among Ashkenazi Jews, accounting for over 90% of the Tay-Sachs disease in that community,
are p.Tyr427Ilefs*5 and a donor splice-junction mutation in intron 12, c.1421+1G>C; these are associated with the severe, infantile-onset disease [226]. The c.1073+1G>A mutation is associated with
severe disease among non-Jewish invididuals, and the p.Gly269Ser mutation results in adult-onset
disease [226]. Mutations causing subacute or chronic forms allow for low levels of residual activity
toward ganglioside GM2 . The level of activity correlates inversely with the severity of the disease. Hex
A pseudodeficiency is caused by point mutations (p.Arg247Trp and p.Arg249Trp) that leave the Hex A
isozyme with reduced but variable activity toward synthetic substrates but with functional ganglioside
GM2 -hydrolyzing activity [213, 226].
Heterozygotes for any of the defects are completely asymptomatic. In the non-Jewish population,
heterozygote frequencies are estimated at 0.006 for HEXA mutations and 0.0036 for HEXB mutations.
Among the Ashkenazi Jewish populations of North America and Israel, a heterozygote frequency of
0.033 was found for HEXA mutations. Genetic counseling and monitoring of at-risk pregnancies have
reduced the incidence of Tay-Sachs disease in the Ashkenazi Jewish population by 90%.
2.12. GM2 gangliosidosis type I (Tay-Sachs disease)
GM2 gangliosidosis type I takes three forms, i.e., variants B and B1 with mutations of the ␣ subunit
of ␤-hexosaminidase, and the AB variant due to mutations in the hexosaminidase activator protein.
The prototype, type B, has a frequency in Ashkenazi Jews of 1 in 4,000. Since the ␣ but not ␤ subunit
is mutated, the total amount of ␤-hexosaminidase is normal, but the hexosaminidase A activity relative
to the total hexosaminidase activity is reduced. Affected infants are normal at birth, but in the first
year of life develop rapidly progressive psychomotor deterioration, seizures, hypotonia, blindness,
dementia and death by 3 to 5 years. The typical cherry-red spot (Fig. 63) is a red area that represents
a normal segment of the retina rendered vivid by contiguous white areas, which contain the stored
material.
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Fig. 63. GM2 gangliosidosis type I (Tay-Sachs disease). The retina shows a cherry-red spot in the macula.

Fig. 64. GM2 gangliosidosis type I (Tay-Sachs disease). (A) Microscopic section of the brain shows large swollen neurons
due to accumulation of ganglioside. (B) Electron micrograph showing characteristic membranous concentric bodies.

The pathologic changes are similar to GM1 gangliosidoses except that in GM2 type I (Tay-Sachs) the
changes are confined to the CNS. Ganglioside accumulation results in massive gliosis and intralysosomal accumulation of lipophilic membranous bodies and MCBs by EM (Fig. 64). The brain is enlarged
early due to the accumulation of storage material in the neurons but becomes atrophic later (Fig. 65).
The Jacob sheep serves as an animal model of Tay-Sachs disease [230]. Carrier screening and prenatal
diagnosis have been established [231].
2.13. GM2 gangliosidosis type II (Sandhoff-Jatzkewitz disease)
Various phenotypes occur within this group, which features a total deficiency of ␤-hexosaminidase
leading to the extensive neuronal and visceral storage of GM2 -gangliosides, glycolipids, glycoproteins, and oligosaccharides [226]. The pattern of inheritance is autosomal recessive, with a predicted
incidence of about 1 in 1,000,000 and no Jewish predominance.
Sandhoff disease usually presents clinically at 3 to 6 months. Clinical signs include mental and
motor delays, doll-like facial appearance, cherry-red spot of the retina, startle response to sound,
macrocephaly, seizures, early blindness, and hypotonia. Death usually occurs by 2 to 5 years [231].
There is also a late-onset variant, with prolonged survival.
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Fig. 65. GM2 gangliosidosis type II (Sandhoff disease). (A) The brain shows atrophy of gyri. (B) On cross section, both gray
and white matter are atrophic.

Sandhoff disease is caused by a deficiency of the enzymes Hex A and Hex B. Hexosaminidase A
cleaves the substrates GM2 , GA2 , globoside, and hexosamine oligosaccharides. All of these substrates
accumulate in Sandhoff disease. Cerebral levels of ganglioside GM2 are increased 100 to 300 times in
Tay-Sachs and Sandhoff disease. A derivative of the ganglioside GM2 and GA2 accumulates to levels
about 20 times normal. Much higher amounts of GA2 accumulate in the brain and viscera in Sandhoff
disease than in Tay-Sachs disease. Globoside accumulates in large quantities in the viscera, especially
in the kidney and spleen in Sandhoff disease, and oligosaccharides accumulate in the tissues and are
excreted. Oligosaccharides appear to be derived from degradation of glycoproteins, which accumulate
because of absence of both Hex A and Hex B [232, 233].
The diagnosis of GM2 gangliosidosis relies upon the assay of hexosaminidase in serum or cultured
fibroblasts. Heterozygotes can be detected using serum. Low total hexosaminidase with a low percentage
of HexB makes the diagnosis of GM2 or a GM2 carrier [226]. All the gangliosidoses and their variants
can be diagnosed prenatally from cultured amniotic fluid cells or chorionic villus biopsies [226].
Several attempts have been made in recent years at enzyme replacement for patients with GM2 gangliosidoses [234], including by an intracerebroventricular route [235]. Other therapies that have been
attempted include pyrimethamine [236–238] and substrate reduction with miglustat [239], but neither
has shown clinical benefits. Investigational therapies under consideration include gene therapy and
chaperone therapy. Supportive treatments include anti-epileptics for seizure control, anti-psychotics,
maintenance of nutrition, and management of infectious diseases.
The pathologic changes in GM2 gangliosidosis are similar to those of the GM1 gangliosidoses. The
cerebral hemispheres appear symmetrical with atrophic gyri (Fig. 66). The pons, medulla, cerebellum,
and spinal cord are atrophic (Fig. 67) and rubbery in consistency. The aortic and mitral valve leaflets
are thickened and distorted, and their histiocytes are filled with storage material. The liver, spleen, and
lymph nodes are normal grossly, and microscopically show minimal storage material. The bone marrow
contains an increased number of foamy, lipid-laden macrophages of storage material on microscopic
examination. In the gastrointestinal tract, the ganglia are remarkably swollen and contain storage
material [233]. EM examination of the brain, spinal cord, retina, liver and spleen document many
intracellular and extracellular concentric laminations within neurons, microglia, ganglion cells and
macrophages (Fig. 68) [101].
2.14. Metachromatic leukodystrophy
The disease was first described by Scholz in 1925 [240], although it wasn’t until decades later that
Scholz’s brain samples were shown to stain metachromatically [241]. Similar cases were reported by
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Figs. 66, 67. GM2 gangliosidosis type II (Sandhoff disease). A coronal section of the brain, normal brain (top) compared
with severe cortical atrophy (bottom); (67) GM2 gangliosidosis type II (Sandhoff disease). A normal spinal cord (top) is
compared with atrophy in Sandhoff disease (bottom).

Fig. 68. GM2 gangliosidosis type II (Sandhoff disease). Electron micrograph of (A) cerebral cortex showing inclusions
of electron-dense profiles with concentric laminations, and (B) liver containing intracellular concentric laminations within
hepatocytes.

Bielschowsky and Henneberg in 1928 [242], and by Greenfield in 1933 [243], accounting for the old
nomenclature of Scholz-Bielschowsky-Henneberg syndrome, or Greenfield disease. The enzymatic
defect was not identified until 1963 [244]. Metachromatic leukodystrophy (MLD) is an autosomal
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recessive lysosomal storage disease with a frequency of 1 in 40,000 caused by deficiency of arylsulfatase A (EC 3.1.6.8) [245, 246]. This enzyme degrades sulfated glycolipids; one of its major substrates
is cerebroside 3-sulfate, a lipid found mainly in myelin membranes, where it accounts for 3% to 4%
of total membrane lipids. Arylsulfatase A removes the sulfate from a galactose residue of cerebroside 3-sulfate with the assistance of saposin B [247]. Deficiencies of this activator protein cause a
very rare disease that is indistinguishable from metachromatic leukodystrophy [247]. In metachromatic leukodystrophy, galactosyl sulfatide (cerebroside sulfate) accumulates in the white matter of
the CNS and in the peripheral nerves. Galactosyl sulfatide, and to a lesser extent lactosyl sulfatide,
also accumulate within the kidney, gallbladder, and certain other visceral organs and are excreted in
excessive amounts in the urine. In histologic preparations, they form spherical granular masses that
stain metachromatically.
The human ARSA gene, on chromosome 22q, contains 8 exons encoding 507 amino acids [246]. Over
180 mutations have been identified [31]. MLD-causing mutations are found in 90-95% of patients [246].
Clinically, metachromatic leukodystrophy is heterogeneous. Three different forms can be distinguished: (i) a severe late-infantile form starting between the ages of 1 and 3 years; (ii) a juvenile form
with an age of onset at 3 to 16 years; and (iii) adult forms that may not become apparent before the
third decade of life. The progression is slower in the late-onset forms and patients may survive for as
much as 20 years after the disease has started. Although the sulfatide storage occurs in all MLD tissues,
it mainly affects the nervous system, leading to progressive demyelination. This demyelination is not
just seen in the central nervous systems, but it also leads to peripheral neuropathy [248], which can
be the presenting sign in adult-onset forms of the disease [249]. Psychiatric symptoms may prevail,
particularly in adult patients, before the neurologic symptoms develop [245]. Proximal renal tubular
acidosis has been described [250], with subclinical metabolic acidosis at baseline, worsening to a
clinically significant acidosis in the acute setting [251]. Sulfatides are known to irritate the gallbladder mucosa, potentially leading to gallbladder papillomatosis [252, 253] and hemobilia [254–256]. A
major determinant of the clinical phenotype is the residual enzyme activity that is associated with a
particular genotype. In the typical case the disease starts at the age of about 18 months. Children lose
acquired capabilities, develop a spastic tetraparesis, dysarthrias, ataxias, dementias, and finally die in a
decerebrate state. In each of the variants, gait disturbance, mental regression, and urinary incontinence
are among the earliest signs. In the childhood variants, other common signs are blindness, loss of
speech, quadriparesis, peripheral neuropathy, and seizures. In the adult, behavioral disturbances and
dementia are the major presenting signs, and the disease may progress slowly over several decades
[245, 246]. It has been hypothesized that the first description of Alzheimer’s disease, presented by
Alois Alzheimer in 1907, was in fact a case of metachromatic leukodystrophy [257].
Arylsulfatase A deficiency can also be observed in individuals who are clinically healthy [258].
This phenomenon has been termed pseudodeficiency. These individuals have only about 10- 20% of
normal enzyme activity. The frequency of this arylsulfatase A pseudodeficiency allele is estimated to
be between 7% and 15%, which predicts that 0.5% to 2% of the population are homozygous and thus
pseudodeficient [259, 260]. Whereas pseudodeficiency is harmless for the carriers, it causes problems
in the diagnosis and genetic counseling of MLD because it is difficult to differentiate pseudodeficiency
from MLD on enzymatic grounds [259].
The diagnosis of MLD relies upon enzymatic assay of arylsulfatase A in leukocytes, dried blood
spots, or fibroblasts, although some patients may have normal activity but deficiency of the enzyme
activator protein or a Km mutant. In addition, some normal individuals may have pseudodeficiency. A
nerve biopsy or detection of urinary sulfatide excretion based on the finding of brown metachromasia
on a filter paper urine spot with cresyl violet may be used for diagnosis (Fig. 69). Although carrier
detection can be problematic, prenatal diagnosis based on arylsulfatase A activity in cultured amniotic
fluid or chorionic villus cells appears to be reliable.
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Fig. 69. Metachromatic leukodystrophy. Urinary spot test showing metachromasia due to the presence of sulfatide (right)
compared to normal (left).
Table 15
Metachromatic leukodystrophy: Pathologic findings
• Destruction of myelin in the cerebral and cerebellar white matter
• Gliosis
• Ballooned macrophages (vacuolated)
• Metachromatic staining of sulfatides in macrophages and white matter
– Basic dyes (e.g., acidified cresyl violet and toluidine blue) stain different colors when
they react with the tissue
– Frozen section tissue must be used
• Subcortical arcuate fibers may be spared
• EM: Prismatic inclusions, representing accumulated sulfatides, can be seen in all tissues

There are few treatment options for MLD. For selected individuals, hematopoietic stem cell transplantation or bone marrow transplantation are options that may slow the progression of symptoms.
In most late-infantile patients, symptoms are progressing rapidly by the time of diagnosis, and the
risks of the procedure may outweigh the possible benefits. In instances in which the diagnosis can be
made presymptomatically and a well-matched donor is available, bone marrow transplantation may
be reasonable. Cell culture modeling suggests that protease inhibitor treatments, enzyme replacement,
and gene replacement therapies could be effective [261]. Lentiviral vectors have been used to transfer a
functional copy of the gene into the patient’s own hematopoietic stems cells, which are subsequentely
reinfused. This approach halted disease progression in three individuals reported to date [262].
The pathologic findings of MLD, summarized in Table 15, involve the cortex, brainstem, cerebellum
(Fig. 70), and spinal cord. There is loss of retinal ganglion cells [263], which accumulate residual bodies
surrounded by a trilaminar membrance [264, 265]. MCB-like inclusions can be seen in anterior horn
cells, neurons in the globus pallidus and large pyramidal neurons of the motor cortex [266]. Cortical
atrophy of the white matter is severe and there is accumulation of sulfatide in the neurons (Fig. 71)
and other sites, notably in the lamina propria of the gastrointestinal tract and the gallbladder that may
become polypoid (Fig. 72). The storage material is autofluorescent (Fig. 73), and can be seen even in
utero [267]. Bile ducts and Kupffer cells in the liver and renal tubular epithelial cells in the kidney
contain storage material (Fig. 74). A sural nerve biopsy also shows metachromatic substance (Fig. 75).
Brown metachromasia is also seen in the pancreatic acinar cells (Fig. 76). Ultrastructurally cytoplasmic
inclusions are seen in oligodendrocytes and astrocytes that may have a herringbone pattern (Fig. 77),
amorphous material, and lamellar structures.
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Fig. 70. Metachromatic leukodystrophy. (A) The white matter in the cerebellum shows brown metachromasia after staining
with cresyl violet. (B) Microscopic section of cerebellum showing brown metachromasia. (C) Dense metachromasia in the
spinal cord.
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Figs. 71, 72. Metachromatic leukodystrophy. (A) The neurons of the cerebral cortex show metachromatic staining with cresyl
violet. (B) Anterior horn cell of spinal cord shows metachromasia with cresyl violet; (72) Metachromatic leukodystrophy.
Vacuolated storage histiocyte cells are present in the lamina propria of the gallbladder.

Fig. 73. Metachromatic leukodystrophy. Autofluorescence of storage cells.
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Figs. 74, 75. Metachromatic leukodystrophy. Microscopic section of the kidney shows brown metochromasia of the renal
tubular epithelial cells; (75) Metachromatic leukodystrophy. A sural nerve biopsy show metachromatic substance within the
nerve fibers.
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Figs. 76, 77. Metachromatic leukodystrophy. Section of the pancreas shows brown metachromasia in the acinar
cells; (77) Metachromatic leukodystrophy. Electron micrograph of a neuron of the white matter shows pleomorphic and
parallel crystalline lipid profiles. Inset, crystalline arrays at high magnification.

2.15. Multiple sulfatase deﬁciency (Austin disease; Metachromatic leukodystrophy variant O)
This disorder is caused by an inability to convert a cysteine, present in at least 7 different sulfatase
enzymes, to 2-amino-3-oxopropionic acid [268]. As a consequence, all of these sulfatases, including
arylsulfatase A, B, and C, are deficient; patients express features of MPS and MLD [269], specifically those of late infantile MLD. Increased amounts of MPS and sulfatide are found in the affected
tissues and in the urine. Hurler-type features are mild and there is rapid psychomotor deterioration.
Peripheral nerve biopsies show brown metachromasia. The disorder may have its onset in the neonatal
period. Congenital hydrocephalus, mild chondrodysplasia calcificans, and heart abnormalities have
been described; patients may later develop ichthyosis and features of MPS. Most patients die in the
first decade.

3. Lysosomal storage diseases due to activator defects
In 1971, Sandhoff and colleagues studied 12 autopsy cases of Tay-Sachs disease [270]. One of the
cases did not have decreased hexosaminidase activity, and in fact the activities of both hexosaminidases
A and B in brain were three to four times higher than in controls. This occurred despite the fact that the
GM2 ganglioside concentration in brain tissue was even higher than that seen in the other patients with
Tay-Sachs disease. In 1978, Conzelmann and Sandhoff demonstrated that this so-called AB variant
of GM2 gangliosidosis was not caused by a hydrolase defect, but by a defective factor needed for
the interaction of the sphingolipid substrate with the water-soluble degrading enzyme [271], the first
time such a mechanism was described. All proven cases of this GM2 activator protein deficiency
have a clinical phenotype indistinguishable from that of classic infantile Tay-Sachs disease [213].
The histopathology is also similar, with widespread storage in the central nervous system, but lack of
visceral involvement [272].
There are five known sphingolipid activator proteins, also known as SAPs or saposins. Four of them
are derived from the same precursor protein, prosaposin, encoded by the PSAP gene on chromosome
10q22.1. These four saposins are highly homologous small proteins of about 80 amino acids each
[273]. The fifth activator protein, GM2 activator protein (also known as SAP-3), is much larger and is
encoded by a separate gene on chromosome 5q33.1.
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Prosaposin exists in two different forms: a 65 kDa form that is targeted to the lysosomes, and a 70
kDa form that is secreted into extracellular fluids. The 65 kDa form enters the lysosome by a mannose6-phosphate independent mechanism. Instead, it has a 17 amino acid sequence in the C-terminal region
that binds sortilin for lysosomal entry [274]. Prosaposin is transported in tandem with procathepsin D,
and once inside the lysosome, it is cleaved into the four saposins A-D by cathepsin D [275]. In addition
to being the precursor for the SAPs, prosaposin itself is known to have neurotrophic effects [276–279].
Sap-A is an activator for galactocerebrosidase and glucocerebrosidase [280]. Little is known about
its mechanism of action, although it is thought to be similar to that of sap-C (see below) [280]. Only one
case of sap-A deficiency has been reported so far, in a patient who had a clinical picture typical of classic
infantile Krabbe disease [281]. The activity of galactocerebrosidase in leukocytes was decreased, but it
was normal in fibroblasts, which led the authors to suspect an activator protein deficiency. Sequencing
of the PSAP gene revealed a mutation in the sap-A coding region.
Sap-B is also known as SAP-1, cerebroside sulfatide activator, or GM1 activator. It activates arylsulfatase A, ␣-galactosidase, ␤-galactosidase and sphingomyelinase [280]. The mechanism of action
is similar to that of the GM2 activator protein, since it binds 1:1 with glycolipids, exerting a detergent
function that solubilizes the lipid so it can interact with its water-soluble hydrolase [273]. The first case
of metachromatic leukodystrophy (MLD) with normal arylsulfatase A activity was reported in 1979
[282]. In 1981, it was first proposed that this phenomenon occurred due to an activator protein deficiency [247]. This form of MLD is also known as the AB variant, while the arylsulfatase A deficiency
is known as the B variant of MLD, in analogy to the nomenclature for the GM2 gangliosidoses [283].
Interestingly, urine from one patient with MLD due to sap-B deficiency not only revealed increased
sulfatide excretion, but also increased levels of globotriaosylceramide, consistent with activation of
␣-galactosidase [284]. This latter patient subsequently received a bone marrow transplant, with no
major clinical improvement noted [285].
Sap-C is also known as SAP-2, and it activates glucocerebrosidase and galactocerebrosidase. Instead
of lipid-protein interaction (as in the case of sap-B and GM2AP), its mechanism of action involves
protein-protein interaction, since it does not bind to glucosylceramide, but to glucocerebrosidase itself
[273]. Its deficiency leads to an atypical form of Gaucher disease with normal glucocerebrosidase
enzyme activity. Of the five patients reported so far, three presented with a type 3 phenotype, while
two siblings had a type 1 presentation [286].
Sap-D is also known as component C. It activates ceramidase and sphingomyelinase. There is no
human case of isolated sap-D deficiency. The mouse with sap-D deficiency exhibits polyuria due to
renal tubular degeneration, and ataxia due to progressive and selective loss of Purkinje cells in the
cerebellum [287].
The deficiency of prosaposin–also known as combined saposin deficiency, or Farber disease type
VII–causes a unique type of lysosomal storage disorder. There are seven known cases, revealing a
uniform picture. The first case was reported in 1989, in a patient who presented immediately after birth
with hyperkinetic movements, myoclonus, respiratory insufficiency and hepatomegaly. He was initially
diagnosed with Gaucher disease since glucocerebrosidase activity was low in leukocytes and fibroblasts, while the activities of arylsulfatase A, ␣-galactosidase, ␤-galactosidase and hexosaminidases A
and B were normal. The patient died at 16 weeks of age, and post-mortem examination revealed additional deficiency of galactocerebrosidase in leukocytes and fibroblasts and ceramidase in fibroblasts.
An amniocentesis was performed during the mother’s next pregnancy, and deficiency of acid ceramidase was found in cultured amniocytes, leading to pregnancy termination. The fetus had contracted
joints. Liver samples from both patients showed increased levels of glucosylceramide, lactosylceramide
and free ceramide. Immunoblot analysis of fibroblast extracts using antibodies against sap-C revealed
absence of staining [288]. Subsequently, a deficiency in sap-B was also detected [289], and a homozygous mutation in the initiation codon of the PSAP gene was found [290]. The third patient described
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had generalized seizures within minutes after birth, as well as hepatosplenomegaly. He died at 3.5
months. A generalized storage process was found in numerous cells, and ultrastructurally the stored
material was membranous with oligolamellar profiles. Neuropathology revealed massive depopulation
of cortical neurons with pronounced fibrillary astrocytosis, as well as a paucity of myelin. There were
increased monohexosylceramides (mainly glucosylceramide), dihexosylceramide (mainly lactosylceramide), globotriaosylceramide, sulfatides, ceramide and globotetraosylceramide, but with normal
cholesterol and sphingomyelin. Immunohistochemistry revealed absence of saposins A-D [291]. The
authors showed evidence that a patient who died at 4 weeks, previously reported as a case of lactosylceramidosis due to NPC [292], in fact had prosaposin deficiency. These two unrelated patients
were from eastern Slovakia, arguing for the existence of a genetic isolate. A homozygous frameshift
mutation leading to nonsense-mediated decay (NMD) was found [291]. The fifth patient had multifocal myoclonus and cyanotic hypoxia immediately after birth, followed by protein-losing enteropathy,
seizures, and death at 17 weeks. Brain MRI revealed gray matter heterotopias. The thymus and mesenteric lymph nodes were devoid of lymphocytes. The pathology was otherwise similar to other cases.
He was found to have a homozygous initiation codon mutation [293]. The sixth patient had myoclonic
bursts, abnormal eye movements, hepatosplenomegaly and seizures, and died at 15 weeks. Brain MRI
also revealed gyral pattern abnormalities. He had a nonsense mutation leading to NMD [294]. The last
reported case had clonic seizures, myoclonus, hepatosplenomegaly, pulmonary infiltrates, optic disc
atrophy and gray matter heterotopias on brain MRI. The patient died at 55 days of life. Analysis of
urinary lipids by tandem mass spectrometry revealed elevated excretion of sulfatides, globotriaosylceramide, lactosylceramide, glucosylceramide, and ceramide. He was found to have a homozygous
splice mutation leading to NMD [295]. Although this condition is rare, it likely remains underdiagnosed, as cases can be confused with Gaucher disease type II. However, several different tests point
towards the right diagnosis, including: 1) lysosomal enzyme assays revealing deficiency not only of
glucocerebrosidase but also galactocerebrosidase and ceramidase; 2) sphingolipid analysis in tissues
or urine, the latter available on a clinical basis, showing elevated excretion of multiple sphingolipids
but with normal cholesterol and sphingomyelin; 3) immunohistochemistry for saposins, revealing lack
of staining; and 4) typical histopathology changes, with marked foamy appearance of storage cells
in visceral organs, and neuronal non-lipid eosinophilic aggregates inside distended lysosomes that
show massive ubiquitination [296]. The combination of generalized lysosomal storage with extreme
depletion of cortical neurons is typical for the condition [293]. The unique neuropathology is thought
to be related to the loss of trophic effects of prosaposin [293, 296]. The adrenal cortex seems uniformly
affected, a feature shared with NPD type A and Wolman disease [293].
4. Lysosomal storage diseases due to transport defects
In contrast to lysosomal enzyme deficiencies, which result in the storage of undegraded macromolecules, lysosomal transport deficiencies cause small molecules to accumulate within lysosomes.
There are many lysosomal transporters, but only five have been associated with human disease, perhaps because redundancy of small molecule carriers prevents pathological accumulation of material.
The five transport defects are cystinosis, Salla disease (free sialic acid storage disease), cobalamin F
disease and cobalamin J disease, and mucolipidosis type IV.
4.1. Cystinosis
In 1903, Abderhalden reported the first case of the disease, that of an infant with failure to thrive,
found on autopsy to have cystine crystals in the liver and spleen. The association with rickets was
first noticed by Lignac in 1924 [297]. The first renal transplant was reported in 1970 [298], and the
defective lysosomal cystine efflux was discovered in 1982 [299].
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Cystinosis is an autosomal recessive lysosomal storage disorder leading to renal tubular Fanconi syndrome in the first year of life, renal glomerular failure by approximately 10 years of age, and growth
retardation, photophobia and hypothyroidism in early childhood. Late complications include myopathy, swallowing difficulty, pancreatic insufficiency, pulmonary dysfunction, retinal blindness, male
hypogonadism, and neurological deterioration in the second to fifth decades, if untreated [300–302].
The disease occurs worldwide, with an estimated incidence of one in 100-200,000. More than 120
mutations have been identified in the causative gene, CTNS [31], which encodes the lysosomal membrane transporter cystinosin [303]. One mutation, a 57,257 bp deletion, accounts for half the cystinosis
cases in Northern Europe and North America [300–302]. CTNS contains 12 exons within 23 kb of
genomic DNA [303].
Cystinosin transports cystine, the disulfide of the free thiol amino acid cysteine, from the lysosome into the cytoplasm [299]; failure to achieve this transport results in the accumulation of free
(nonprotein) cystine in the lysosomes of most cells of the body. The crystals are birefringent under
cross-polarizing light (Fig. 78) and form in the kidney, spleen, liver, intestine, cornea, conjunctiva,
bone marrow, pancreas, testis, muscle, and other tissues due to cystine’s low solubility in aequeous
fluids. The classic disease causes renal failure early, but variants exist with milder clinical courses
[300–302]. Older patients can present with a distal vacuolar myopathy; the vacuoles stain positively
with acid phosphatase, are not birefringent under a polarized filter–indicating they do not contain
cystine crystals–and are filled with an amorphous, unidentified material when evaluated by electron
microscopy [304].
The diagnosis of cystinosis is based upon cystine measurements in circulating leukocytes or by
finding corneal crystals on slit lamp examination of the eyes (Fig. 79). Molecular confirmation is also
possible. Prenatal diagnosis is available by performing cystine measurements or molecular diagnostics
on cultured amniocytes or samples of chorionic villi [300–302].
Treatment is both supportive and directed toward the basic defect. Symptomatic therapy involves
replacement of renal losses with supplements such as citrate, phosphate, potassium, calcium, sodium,
and carnitine [300–302]. Vitamin D is often helpful in promoting gastrointestinal phosphate absorption.
Free access to water is essential. Some patients require L-thyroxine replacement for hypothyroidism
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Figs. 78, 79. Light micrograph under birefringent light showing cystine crystals of various shapes. Aequeous fixative has
smoothed the hexagonal and rectangular edges; (79) Slit lamp examination of cornea of a child with cystinosis showing a
multitude of crystals.
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and dark glasses for photophobia. Young patients respond to growth hormone injections; some older
patients require insulin; occasionally, older males benefit from testosterone supplements. Treatment
aimed at the primary defect involves cysteamine, which depletes cystinosis cells of their lysosomal
cystine content. This is possible because it severs the disulfide bond of cystine to form cysteinecysteamine mixed disulfide, structurally similar to lysine, that can then be exported from the lysosome
by a cationic amino acid transporter encoded by PQLC2 [305]. Oral cysteamine (Cystagon® ) prevents
or retards renal glomerular deterioration [306], enhances growth, and prevents most or all of the
late complications of cystinosis [307]. A delayed-release cysteamine (Procysbi® ) formulation is also
available [308]. Cysteamine eyedrops dissolve corneal cystine crystals [309]. If renal function is lost,
dialysis serves as a temporizing measure until a renal allograft can be provided. Kidney transplants
perform well in cystinosis patients.
4.2. Free sialic acid storage disease
Salla disease carries the name of the municipality in Finnish Lapland where the disease was first
described in 1979 [310]. Infantile free Sialic acid Storage Disease (ISSD) was first described in 1982
[311]. Salla disease and ISSD are rare allelic disorders of free sialic acid characterized by accumulation
of the charged monosaccharide sialic acid (N-acetylneuraminic acid) in lysosomes [312]. The basic
defect in these disorders involves failure to transport sialic acid out of lysosomes [313, 314].
Typically, Salla disease patients are normal at birth but develop muscular hypotonia and ataxia
between 6 and 12 months of age. Nystagmus and seizures can also occur. Motor development is always
delayed, with an average age at walking of 4 years [312]. Other developmental milestones are lost over
time. Growth is delayed, head circumference is normal and there is no hepatosplenomegaly. Coarse
facial features generally develop later in adulthood. Scoliosis is present in less than half of the patients.
Cognitive ability is severely impaired. The mean age at death in Salla disease is 34.6 years [312].
The clinical course of ISSD is more severe than that of Salla disease and usually leads to death in early
infancy, with a mean age at death of 13.1 months [315]. Hydrops fetalis and/or ascites can occur [315].
All ISSD patients demonstrate failure to thrive, hypotonia, hepatosplenomegaly, growth retardation
and markedly delayed psychomotor development in early infancy [312]. Hypopigmentation of the skin
and hair, mild skeletal dysplasias, and coarse facial features are also seen. Nephrotic syndrome is not
uncommon [315, 316]. Electron microscopy of renal biopsies can reveal swollen epithelial, endothelial
and mesangial cells filled with membrane-bound, electron-lucent vacuoles [315, 316]. Storage material
accumulates in CNS neurons and astrocytes, associated with severe demyelination, gliosis and marked
hypoplasia of the corpus callosum [315, 317, 318]. Staining of neurons, endothelial cells and Kupffer
cells using the sialic acid-specific lectin wheat germ agglutinin, identifies the storage material as sialic
acid [317].
The diagnosis of Salla disease or ISSD relies upon the finding of increased urinary excretion of
free sialic acid. In Salla disease, the levels range from 5 to 20 times normal (280–2100 nmol/mg
creatinine), while in ISSD urine sialic acid excretion is increased up to two-hundred-fold (1071–14230
nmol/mg creatinine) [312]. Sialic acid is also elevated in cultured fibroblasts from Salla disease and
ISSD patients. Electron microscopic studies of skin, kidney and liver from sialic acid storage disease
patients reveal numerous electron-lucent membrane-bound vacuoles in various cell types [310, 311,
315, 317, 319]. Vacuoles are also present in cultured fibroblasts from patients and can sometimes be
observed in peripheral blood lymphocytes [310].
Mutations in SLC17A5, coding for the transport protein sialin, were found in both Salla disease and
ISSD patients. A homozygous missense mutation (c.115C>T; p.Arg39Cys) in SLC17A5 is present in all
Finnish Salla disease patients [320]. There is a founder mutation causing ISSD in the Inuit population
[321]. There is no known treatment for either Salla disease or ISSD.
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4.3. Cobalamin F and cobalamin J disease
David Rosenblatt first described a defect in lysosomal vitamin B12 egress, leading to accumulation
of non-protein bound cobalamin intralysosomally [322]. The underlying molecular defect was not
known until 2009, when mutations in the LMBRD1 gene were described [323]. Mutations in ABCD4
were shown to lead to a similar defect in lysosomal cobalamin efflux [324]. It has been postulated
that the proteins encoded by LMBRD1 and ABCD4 form a membrane-bound complex that delivers
cobalamin from the lysosome directly to MMACHC in the cytoplasm, thus preventing cytoplasmic
dilution or inactivation of cobalamin [325].
There are only a handful of known patients in the world with either of these lysosomal cobalamin
disorders, and they have a combination of the clinical manifestations of homocystinuria and methylmalonic acidemia, since cobalamin is needed for both of the pathways involved. One feature that
differentiates the lysosomal cobalamin disorders from the other inborn errors of cobalamin metabolism
is that patients tend to have low serum levels of vitamin B12. In addition, patients with cblF disease
commonly have recurrent or persistent stomatitis, while two out of four patients with cblJ disease had
skin hyperpigmentation that improved after treatment [326, 327], features not commonly seen in other
cobalamin defects.
4.4. Mucolipidosis IV (Berman syndrome)
The disease was first described by Berman and colleagues in 1974 [328]. It is characterized by
intellectual disabilities, corneal clouding, retinal degeneration, and achloridia leading to hypergastrinemia [329]. Histopathologically, there are lamellar membranous cytoplasmic bodies, as well as single
membrane-bound vacuoles filled with fibrillogranular material in various cell types [328]. Mutations in
MCOLN1 (also known as TRPML1) were first identified in 2000 [330]. The gene encodes mucolipin-1,
a cationic channel located in late endosomes and lysosomes that transports calcium, sodium, potassium
[330] and iron [331]. Calcium release from the lumen of late endosomes and lysosomes into the cytosol
is needed for fusion of these organelles, a critical step in membrane trafficking. Thus, inactivation of
mucolipin-1 leads to abnormal storage of lipids and other compounds within late endosomes, since their
content cannot be degraded in the lysosomes due to lack of fusion with these organelles [332]. In addition, lysosomal calcium efflux through mucolipin-1 activates calcineurin, thus promoting the nuclear
translocation of TFEB, a master transcriptional regulator of lysosomal biogenesis and autophagy [333].
5. Acquired lysosomal storage disorders
Phospholipidosis consists of the exaggerated storage of phospholipids inside lysosomes, which
acquire a multilamellar appearance [334]. There are more than fifty drugs that can cause this, including
antiarrhythmics, antimalarials, antipsychotics, antibacterials, and others [334]. All these compounds
are cationic amphiphilic drugs, with a hydrophobic ring and a hydrophilic side chain charged with a
cationic amine group [334]. Drug-induced phospholipidosis is considered an acquired form of lysosomal storage disorder, since the offending drugs are thought to inhibit lysosomal phospholipases
[335]. Histopathologically, the cells acquire a foamy appearance, and ultrastructurally there is storage of multi-lamellar whorled membranes, or “myeloid bodies” [335]. As an example, amiodarone
can induce the appearance of these inclusion bodies not just in intra-alveolar foamy macrophages,
but also in hepatocytes, tissue macrophages, lymphocytes, granulocytes and plasma cells [336].
In fact, the cutaneous hyperpigmentation induced by amiodarone is the result of lysosomal storage of
this lipid-like material [337]. In the case of chloroquine-induced phospholipidosis, the cell types most
commonly involved are renal cells, endothelial cells, cardiomyocytes and skeletal muscle cells [338].

C.R. Ferreira and W.A. Gahl / Lysosomal storage diseases

55

In addition to the whorled inclusions seen in other types of phospholipidoses, curvilinear bodies can
be seen in skeletal and cardiac muscle cells, and to some extent in renal cells, in cases of chloroquine
toxicity [338]. Heart involvement can lead to hypertrophic [339] or restrictive cardiomyopathy, even
necessitating heart transplant in severe cases [340]. Similar myeloid bodies and curvilinear bodies
can be seen in cases of hydroxychloroquine-induced cardiomyopathy [341]. The renal phospholipidosis induced by chloroquine mimics the histopathology of Fabry disease [342], and has led to its
misdiagnosis [338]. Bis(monoacylglycerol)phosphate (BMP) is an anionic phospholipid found exclusively in lysosomes and late endosomes [335], and di-22:6-BMP is considered a reliable biomarker of
drug-induced phospholipidosis that can be monitored in serum and urine [343].

6. Treatment and screening of lysosomal storage diseases
There is safe and efficacious treatment for only a fraction of the known lysosomal disorders. Others
are being investigated (e.g., Niemann-Pick disease, Sly syndrome, Farber disease). Even for those
disorders for which therapy is available, early detection, before the onset of irreversible changes,
is critical. This applies to bone marrow transplantation in some of the enzyme deficiencies as well
as cysteamine treatment for cystinosis. Hence, newborn screening would be a huge benefit for the
treatment of lysosomal storage disorders. Various techniques have been proposed in order to screen
for lysosomal diseases, such as 1) direct measurement of enzyme activity, either by tandem mass
spectrometry or by digital microfluidics fluorometric assays; 2) measuring the abundance of lysosomal
enzymes through immunological assays; or 3) assaying biomarkers. The most studied techniques have
involved directly measuring enzyme activity, and mass spectrometry appears to better differentiate
affected from non-affected individuals when compared to fluorometric assays [344].
Several states have published their experience with newborn screening for lysosomal storage disorders. After screening 110,000 newborns from Washington state, a prevalence of 1/7,800 was estimated
for Fabry disease males, 1/27,800 for Pompe disease, and 1/35,500 for Hurler disease, 2–4 times
greater than the prevalence estimated on clinical grounds [345]. Missouri reported their experience
with screening 43,701 specimens during the first 6 months of their pilot study, and found a detection
rate of 1/2,913 for Fabry disease, 1/5,463 for Pompe disease, 1/14,567 for Hurler disease and 1/43,701
for Gaucher disease [346].
The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was convened by the United States Secretary of Health and Human Services with the purpose of reviewing
the evidence and impact on public health of disorders that might be added to the newborn screening
panel. After reviewing the evidence, this committee advises the Secretary on whether or not the condition in question should be added to a Recommended Uniform Screening Panel (RUSP). Although
the ACHDNC makes recommendations regarding which conditions to screen for on a national level,
each state decides which disorders will be included in their newborn screening panel. Hence, Pompe
disease was added to the RUSP in February 2015, and Hurler disease was added to the RUSP in March
2016, but as of mid-2016 only four states were providing universal screening for Pompe disease, and
only three states were providing universal screening for Hurler disease.
Newborn screening for LSDs is not unique to the United States, and in fact one of the first largebased pilot studies came from Austria, where the incidence of Fabry disease was 1/3,859 newborns,
Pompe disease 1/8,684 births, and Gaucher disease 1/17,368 births, after screening 34,736 newborns
[347]. Newborn screening in Taiwan led to the identification of the cardiac variant of Fabry disease
in 1/1,600-2,450 male newborns [146, 348]. A study from Italy screened 37,104 newborn males for
Fabry disease, and found an incidence of 1/3,100–4,600, with a ratio of later-onset:classic-onset of
7–11:1 [349]. This increased incidence of disease when using newborn screening appears related to
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an increased diagnosis of later-onset forms of the disease, regardless of the lysosomal storage disorder
being screened [345, 347]. This fact raises ethical concerns about performing newborn screening for
LSDs, since the majority of cases diagnosed in the newborn period will not manifest any symptoms
until adulthood. This is not the only issue that plagues the implementation of newborn screening for
LSDs. Since the most common technique used for newborn screening involves the measurement of
lysosomal enzyme activity, populations that have a high prevalence of pseudodeficiency alleles will also
have a high percentage of false positive results. As an example, homozygosity for the ␣–glucosidase
pseudodeficiency allele is found in 3.3–3.9% of Asians [350], although different algorithms have been
created in order to increase the positive predictive value of the test in this population [351]. Perhaps
more importantly, the early identification of a disorder does not always lead to a better clinical outcome.
As an example, New York state published their experience after screening almost 2 million infants for
Krabbe disease, and found five individuals with early infantile Krabbe disease. Of those, four received
hematopoietic stem cell transplants, with two dying from complications of the transplant, and the other
two still having moderate to severe developmental delay after the transplant [352]. Thus, although the
technology exists to permit us to screen for multiple LSDs, early diagnosis will not always lead to
clinical benefit, at least until better treatment options become available.
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GM2 gangliosidosis mimicking spinal muscular atrophy, Gene 527(2) (2013), 679–682.
[226] M.M. Kaback and R.J. Desnick. Hexosaminidase A Deficiency. In: R.A. Pagon, M.P. Adam, H.H. Ardinger, S.E.
Wallace, A. Amemiya, L.J. Bean, et al., editors. GeneReviews(® ) [Internet]. Seattle (WA) University of Washington,
Seattle; 1993 [cited 2015 Aug 3]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1218/
[227] M.S. Salman, J.T. Clarke, G. Midroni and M.B. Waxman, Peripheral and autonomic nervous system involvement in
chronic GM2-gangliosidosis, J Inherit Metab Dis 24(1) (2001), 65–71.
[228] M. Pellegrini, E. Zicari, M.T. Dotti and A. Federico, Dysautonomic achalasia in two siblings with Sandhoff disease,
J Neurol Sci 241(1-2) (2006), 107–109.
[229] G.C. Chow, J.T. Clarke and B.L. Banwell, Late-onset GM2 gangliosidosis presenting as burning dysesthesias, Pediatr
Neurol 25(1) (2001), 59–61.
[230] P.A. Torres, B.J. Zeng, B.F. Porter, J. Alroy, F. Horak and J. Horak, et al., Tay-Sachs disease in Jacob sheep, Mol
Genet Metab 101(4) (2010), 357–363.
[231] M. Kaback, J. Lim-Steele, D. Dabholkar, D. Brown, N. Levy and K. Zeiger, Tay-Sachs disease–carrier screening,
prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data
Collection Network, JAMA 270(19) (1993), 2307–2315.
[232] B. Rosengren, J.E. Månsson and L. Svennerholm, Composition of gangliosides and neutral glycosphingolipids of
brain in classical Tay-Sachs and Sandhoff disease: More lyso-GM2 in Sandhoff disease? J Neurochem 49(3) (1987),
834–840.

66

C.R. Ferreira and W.A. Gahl / Lysosomal storage diseases

[233] P.A. Bolhuis, J.G. Oonk, P.E. Kamp, A.J. Ris, J.C. Michalski and B. Overdijk, et al., Ganglioside storage, hexosaminidase lability, and urinary oligosaccharides in adult Sandhoff’s disease, Neurology 37(1) (1987), 75–81.
[234] D. Tsuji, H. Akeboshi, K. Matsuoka, H. Yasuoka, E. Miyasaki and Y. Kasahara, et al., Highly phosphomannosylated
enzyme replacement therapy for GM2 gangliosidosis, Ann Neurol 69(4) (2011), 691–701.
[235] K. Matsuoka, T. Tamura, D. Tsuji, Y. Dohzono, K. Kitakaze and K. Ohno, et al., Therapeutic potential of intracerebroventricular replacement of modified human ␤-hexosaminidase B for GM2 gangliosidosis, Mol Ther J Am Soc
Gene Ther 19(6) (2011), 1017–1024.
[236] J.T.R. Clarke, D.J. Mahuran, S. Sathe, E.H. Kolodny, B.A. Rigat and J.A. Raiman, et al., An open-label Phase I/II
clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or
Sandhoff variants), Mol Genet Metab 102(1) (2011), 6–12.
[237] E. Osher, A. Fattal-Valevski, L. Sagie, N. Urshanski, Y. Amir-Levi and S. Katzburg, et al., Pyrimethamine increases
␤-hexosaminidase A activity in patients with Late Onset Tay Sachs, Mol Genet Metab 102(3) (2011), 356–363.
[238] E. Osher, A. Fattal-Valevski, L. Sagie, N. Urshanski, N. Sagiv and L. Peleg, et al., Effect of cyclic, low dose
pyrimethamine treatment in patients with Late Onset Tay Sachs: An open label, extended pilot study, Orphanet J
Rare Dis 10 (2015), 45.
[239] B.E. Shapiro, G.M. Pastores, J. Gianutsos, C. Luzy and E.H. Kolodny, Miglustat in late-onset Tay-Sachs disease: A
12-month, randomized, controlled clinical study with 24 months of extended treatment, Genet Med Off J Am Coll
Med Genet 11(6) (2009), 425–433.
[240] W. Scholz, Klinische, Pathologisch-Anatomische und Erbbiologische untersuchungen bei Familiärer, Diffuser hirnsklerose im Kindesalter, Z Für Gesamte Neurol Psychiatr 99(1) (1925), 651–717.
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[242] M. Bielschowsky and R. Henneberg, Über familiäre diffuse Sklerose (Leukodystrophia cerebri progressiva hereditaria), J Psychol NeurolLpz 36 (1928), 131–181.
[243] J.G. Greenfield, A Form of Progressive Cerebral Sclerosis in Infants associated with Primary Degeneration of the
Interfascicular Glia, Proc R Soc Med 26(6) (1933), 690–697.
[244] J.H. Austin, A.S. Balasubramanian, T.N. Pattabiraman, S. Saraswathi, D.K. Basu and B.K. Bachhawat, A controlled
study of enzymatic activies in three human disorder of glycolipid metabolism, J Neurochem 10(11) (1963), 805–816.
[245] V. Gieselmann and K.-M. Ingeborg, Metachromatic Leukodystrophy. In: D.L. Valle, A.L. Beaudet, B. Vogelstein,
K.W. Kinzler, S.E. Antonarakis, A. Ballabio, et al., editors. The Online Metabolic and Molecular Bases of Inherited
Disease [Internet]. New York, NY: The McGraw-Hill Companies, Inc.; 2014 [cited 2015 Jul 27]. Available from:
http://mhmedical.com/content.aspx?aid=1102896204
[246] A.L. Fluharty, Arylsulfatase A Deficiency. In: R.A. Pagon, M.P. Adam, H.H. Ardinger, S.E. Wallace, A. Amemiya,
L.J. Bean, et al., editors. GeneReviews(® ) [Internet]. Seattle (WA) University of Washington, Seattle; 1993 [cited
2015 Aug 3]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1130/
[247] R.L. Stevens, A.L. Fluharty, H. Kihara, M.M. Kaback, L.J. Shapiro and B. Marsh, et al., Cerebroside sulfatase
activator deficiency induced metachromatic leukodystrophy, Am J Hum Genet 33(6) (1981), 900–906.
[248] P.S. Bindu, A. Mahadevan, A.B. Taly, R. Christopher, N. Gayathri and S.K. Shankar, Peripheral neuropathy in
metachromatic leucodystrophy. A study of 40 cases from south India, J Neurol Neurosurg Psychiatry 76(12) (2005),
1698–701.
[249] M. Sabatelli, L. Quaranta, F. Madia, G. Lippi, A. Conte and M.L.o. Monaco, et al., Peripheral neuropathy with
hypomyelinating features in adult-onset Krabbe’s disease, Neuromuscul Disord NMD 12(4) (2002), 386–391.
[250] J. Rodriguez-Soriano, J.M. Rivera, A. Vallo, J.M. Prats-Viñas and G. Castillo, Proximal renal tubular acidosis in
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[290] D. Schnabel, M. Schröder, W. Fürst, A. Klein, R. Hurwitz and T. Zenk, et al., Simultaneous deficiency of sphingolipid
activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene, J Biol Chem 267(5)
(1992), 3312–3315.
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